The present invention relates to nitric oxide-releasing particles. More particularly, the present application relates to S-nitrosothiol-modified silica particles.
Since the discovery of the physiological roles of nitric oxide (NO), much research has focused on the synthesis of NO-releasing materials/vehicles to elicit NO's characteristics as an antimicrobial agent, mediator of wound repair, or angiogenic cofactor. S-Nitrosothiols (RSNOs) are one class of endogenous NO donor believed to store/transport the majority of the body's natural reservoir of NO. As such, a large body of work has utilized low molecular weight RSNOs (e.g., S-nitroso-glutathione (GSNO), S-nitroso-N-acetylcysteine (SNAC), and S-nitroso-N-acetyl-penicillamine (SNAP)) as donors to spontaneously release NO. Although promising, the clinical application of low molecular weight NO donors has been slow due to both lack of tissue specific targeting and uncontrollable NO release kinetics. To address such shortcomings, NO donor precursors have been conjugated to larger scaffolds (e.g., proteins, dendrimers, and nanoparticles), thus enabling high NO storage per delivery vehicle and release profiles similar to their small molecule analogues.
Silica particles are among the most widely employed macromolecular scaffolds for biomedical applications due to facile synthetic strategies and minimal cytotoxicity. Previously, the surface of fumed silica particles (7-10 nm diameter) have been grafted with SNAP, SNAC, and S-nitrosocysteine (CysNO) to create S-nitrosothiol-modified silica particles. However, the NO storage was limited to 0.021-0.138 μmol mg−1 because the thiol functionalization was restricted to the exterior of the particle. Additionally, these systems are not able to tune particle size to fit a therapeutic system of interest. Alternatively, the hydrolysis and co-condensation of organosilane and tetraalkoxysilane precursors via sol-gel chemistry may represent a method for preparing a silica network with a higher concentration of organic functionalites. Indeed, the Stöber process (sol-gel chemistry with an alcohol solvent and an ammonia catalyst) has proven effective for synthesizing N-diazeniumdiolate-modified silica particles of diverse size and NO storage capacity. See, for example, U.S. Publication No. 2009/0214618 (Schoenfisch et al.), which is herein incorporated by reference in its entirety. The advantage of the Stöber method over surface grafting is that the co-condensation provides uniform incorporation of the organic (i.e., NO donor) functionality throughout the resulting silica network as opposed to restricted functionalization at the surface alone. As a result, such particles may exhibit significantly increased NO storage.
A first aspect of the present invention comprises a method of forming S-nitrosothiol-functionalized co-condensed silica particles comprising:
A second aspect of the present invention comprises S-nitrosothiol-functionalized monodisperse co-condensed silica particles having an average particle diameter in a range of about 10 nm to about 100 μm.
A further aspect of the present invention comprises S-nitrosothiol-functionalized co-condensed silica particles having an NO storage in a range of about 0.01 μmol to about 10 μmol NO per mg particle.
Another aspect of the present invention comprises a S-nitrosothiol-functionalized co-condensed silica particle comprising tertiary nitrosothiol functional groups.
A further aspect of the present invention comprises a compound having the following structure:
wherein R, R′ and R″ are each independently alkyl and n is 0 in a range of 0 to 10.
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this application, illustrate certain embodiment(s) of the invention.
The foregoing and other aspects of the present invention will now be described in more detail with respect to the description and methodologies provided herein. It should be appreciated that the invention can be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the embodiments of the invention and the appended claims, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Also, as used herein, “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items. Furthermore, the term “about,” as used herein when referring to a measurable value such as an amount of a compound, dose, time, temperature, and the like, is meant to encompass variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% of the specified amount. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. Unless otherwise defined, all terms, including technical and scientific terms used in the description, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
All patents, patent applications and publications referred to herein are incorporated by reference in their entirety. In the event of conflicting terminology, the present specification is controlling.
The embodiments described in one aspect of the present invention are not limited to the aspect described. The embodiments may also be applied to a different aspect of the invention as long as the embodiments do not prevent these aspects of the invention from operating for its intended purpose.
Chemical Definitions
As used herein the term “alkyl” refers to C1-20 inclusive, linear (i.e., “straight-chain”), branched, or cyclic, saturated or at least partially and in some cases fully unsaturated (i.e., alkenyl and alkynyl)hydrocarbon chains, including for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, and allenyl groups. “Branched” refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl or propyl, is attached to a linear alkyl chain. Exemplary branched alkyl groups include, but are not limited to, isopropyl, isobutyl, tert-butyl. “Lower alkyl” refers to an alkyl group having 1 to about 8 carbon atoms (i.e., a C1-8 alkyl), e.g., 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms. “Higher alkyl” refers to an alkyl group having about 10 to about 20 carbon atoms, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. In certain embodiments, “alkyl” refers, in particular, to C1-5 straight-chain alkyls. In other embodiments, “alkyl” refers, in particular, to C1-5 branched-chain alkyls.
The term “mercapto” or “thio” refers to the —SH group.
Provided herein according to some embodiments of the invention are methods of forming co-condensed silica particles via the Stöber process. See, e.g., Stöber, W.; Fink, A.; Bohn, E. J. Colloid Intel face Sci. 1968, 26, 62 (incorporated by reference herein in its entirety). Particle formation under the Stöber process proceeds upon hydrolysis and condensation of silane precursors where the relative hydrolysis rates for the precursors dictate both the speed of particle growth and the likelihood of each silane's incorporation into the silica network. Excessive disparities between reaction rates of different silanes may lead to absence of particle formation upon attempted co-condensation.
Provided according to some embodiments of the invention are methods of forming S-nitrosothiol-functionalized co-condensed silica particles that include reacting a thiol-containing silane and a backbone alkoxysilane in a sol precursor solution that includes water to form thiol-functionalized co-condensed silica particles, wherein the thiol-functionalized co-condensed silica particles include a polysiloxane matrix and at least some of thiol groups are present within the polysiloxane matrix. In some embodiments of the invention, the methods further include reacting the thiol-functionalized co-condensed silica particles with a nitrosating agent to provide the S-nitrosothiol-functionalized co-condensed silica particles.
Any suitable thiol-containing silane may be used. In some embodiments, the thiol-containing silane includes a primary thiol, in some embodiments, a secondary thiol, and in some embodiments, a tertiary thiol. Combinations of different silanes may also be used. A suitable thiol-containing silane will be a silane that will allow for particle formation, and in some embodiments, monodisperse particle formation. Thus, some thiol-containing silanes may be suitable with some backbone alkoxysilanes and not suitable with others. In some embodiments, the primary thiol-containing silane is mercaptopropyltrimethoxysilane. In some embodiments, the tertiary thiol alkoxysilane has the following structure: (OR)(OR′)(OR″)Si(Rx), wherein R, R′ and R″ are each independently H, alkyl or substituted alkyl and Rx is functional group that comprises a tertiary thiol group. In particular embodiments, the tertiary thiol alkoxysilane has the structure:
wherein R, R′ and R″ are each independently H, alkyl or substituted alkyl and n is 0-10. In some embodiments, R, R′ and R″ are each independently alkyl and n is 0-5. Furthermore, in particular embodiments of the invention, the tertiary thiol is a compound having the structure:
Any suitable backbone alkoxysilane may be used. As used herein, the term “backbone alkoxysilane” refers to an alkoxysilane that does not contain a thiol functional group. Examples include tetramethoxysilane, tetraethoxysilane, methyltrimethoxysilane, methyltriethoxysilane and butyltrimethoxysilane. A suitable backbone silane will be a silane that will allow for particle formation, and in some embodiments, monodisperse particle formation.
Any suitable concentration of water may be used. In some embodiments, the water concentration in the sol precursor solution is in a range of about 8 M to about 32.5 M.
In some embodiments, a catalyst, such as an ammonia catalyst, is included in the sol precursor solution. Any suitable concentration of catalyst may be used. However, in some embodiments, an ammonia catalyst is included in the sol precursor solution, in some embodiments, at a concentration in a range of about 1.9 M to about 5.5 M.
In particular embodiments of the invention, mercaptopropyltrimethoxysilane and tetramethoxysilane are reacted in the presence of water and an ammonia catalyst to form thiol-functionalized co-condensed silica particles. In some embodiments, the reaction occurs in a solution that includes mercaptopropyltrimethoxysilane and tetramethoxysilane at a total silane monomer concentration in a range of about 0.1 M to about 0.4 M, wherein the silane monomer includes about 25 to about 85 mol % mercaptopropyltrimethoxysilane. In some embodiments, water is present in the solution at a concentration in a range of about 8.0 to about 32.5 M and the ammonia catalyst is present at a concentration in a range of about 1.9 M to about 5.5 M.
In some embodiments of the invention, mercaptopropyltrimethoxysilane and tetraethoxysilane are reacted in the presence of water and an ammonia catalyst to form thiol-functionalized co-condensed silica particles. In some embodiments, the reaction occurs in a solution that includes mercaptopropyltrimethoxysilane and tetraethoxysilane at a total silane monomer concentration in a range of about 0.1 M to about 0.4 M, wherein the silane monomer includes about 75 to about 85 mol % mercaptopropyltrimethoxysilane. In some embodiments, water is present in the solution at a concentration in a range of about 8.0 to about 32.5 M and the ammonia catalyst is present at a concentration in a range of about 1.9 M to about 5.5M.
In some embodiments, methods of forming thiol-functionalized co-condensed silica particles include reacting a tertiary thiol-containing silane and a backbone alkoxysilane in the presences of water and an ammonia catalyst to form thiol-functionalized co-condensed silica particles. In some embodiments, the reaction occurs in a solution that includes tertiary thiol-containing silane and alkoxysilane at a total silane monomer concentration in a range of about 0.1 M to about 0.4 M, wherein the silane monomer includes about 25 to about 85 mol % tertiary thiol-containing silane. In some embodiments, water is present in the solution at a concentration in a range of about 8.0 to about 32.5 M and the ammonia catalyst is present at a concentration in a range of about 1.9 to about 5.5 M.
The sol precursor solution may also be stirred/agitated as known to those of skill in the art, and other additives or silane monomers used in sol chemistry may be included in some embodiments of the invention.
In some embodiments of the invention, methods provided herein may be used to form nitrosothiol-functionalized co-condensed silica particles, which in some embodiments, are monodisperse. As used herein, the term “monodisperse” refers to particles having a uniform particle size, in some embodiments, having an average particle diameter ±100 nm as measured from electron micrographs; a Z-average ±60 nm as measured from dynamic light scattering; and/or having a polydispersity index ≦0.1 as measured via dynamic light scattering. In some embodiments, the methods described herein provide monodisperse particles having an average particle diameter of less than 100 microns, and in some embodiments, less than 1 micron. In particular embodiments, the methods used herein may provide monodisperse particles having an average particle diameter in a range of about 10 nm to about 100 μm. In some embodiments, the particles have an average particle diameter in a range of about 200 to about 700 nm.
Any suitable method of nitrosating the thiol-functionalized co-condensed silica particles may be used. Further, any suitable nitrosating agent may be used. However, in some embodiments, the nitrosating agent includes acidified sodium nitrite, alkyl nitrites, including tertbutyl nitrite and isopentyl nitrite, and various nitrogen oxides including nitrous oxide, N2O3, N2O4 and NO2. Examples of nitrosation may be found in Williams, D. L. H. Acc. Chem. Res. 1999, 32, 869, the contents of which are incorporated herein by reference in their entirety.
In some embodiments of the invention, the nitrosation chemistry conserves particle size integrity and yields monodisperse S-nitrosothiol-functionalized co-condensed silica particles. No changes in particle size have been observed following addition of the nitric oxide functionality to the macromolecular structure, a drawback that has been observed with other nitrosothiol-modified macromolecular donors. Furthermore, as shown below in the Examples, the thiol-functionalized co-condensed silica particles may be sonicated prior to nitrosation without deleteriously affecting the NO storage and/or morphology of the particles.
The co-condensed silica particles may include S-nitrosothiol groups throughout the particle, and as such, may provide enhanced NO storage properties. For example, in some embodiments of the invention, provided are S-nitrosothiol-functionalized co-condensed silicas particles that have an NO storage in a range of about 0.01 μmol to about 10 μmol NO per mg particle, and in some embodiments, 0.09 μmol to about 4.40 μmol NO per mg particle.
The incorporation of the S-nitrosothiol groups throughout the interior of the silica particle structure may also afford unexpected stability. Glutathione and other thiols are known to one skilled in the art to be a vial trigger for RSNO decomposition and release a variety of NOx species. In some embodiments of the invention, the low porosity of the S-nitrosothiol-functionalized co-condensed silica particles protect the RSNO donors from premature decomposition by glutathione or other blood components, adding a level of nitric oxide stability when used in drug delivery applications.
Acetic anhydride (96 mmol, 9.80 g) was added dropwise to a well stirred solution of D-(−) penicillamine (40 mmol, 5.97 g) in pyridine (50 mL) at 0° C. After 30 min, the flask was removed from ice and allowed to stir at room temperature for 15 h. The resultant orange solution was partitioned between chloroform and dilute HCl and washed 4× with dilute HCl. After drying over MgSO4, the organic phase was evaporated to yield an orange residue. The residue was first dissolved in absolute ethanol (20 mL), and then precipitated in pentane at −78° C. The light yellow crystalline product was isolated by filtration (2.07 g, 30%). 1H NMR (CDCl3) δ1.65 (s, CH3), 1.86 (s, CH3), 2.05 (s, NHCOCH3), 5.68-5.70 (d, CH(CH3)2), 6.56 (NHCOCH3). 13C NMR (CDCl3) δ 22.52 (NHCOCH3), 26.20 (CH(CH3)2), 30.22 (CH(CH3)2), 51.23 (CH), 169.37 (NHCOCH3), 192.21 (SCO).
Synthesis of N-Acetyl Penicillamine Propyltrimethoxysilane (NAPTMS). APTMS (10 mmol, 1.78 g). was added to a stirring solution of NAP thiolactone (10 mmol, 1.72 g) in methylene chloride (20 mL). The light yellow solution was stirred for 4 h at room temperature before distillation of the methylene chloride to yield NAPTMS as a viscous clear oil. 1H NMR (CDCl3) δ 0.54 (t, SiCH2), 1.24 and 1.39 (s, CH(CH3)2SH), 1.54 (m, SiCH2CH2), 1.96 (s, NHCOCH3), 2.96 and 3.21 (m, SiCH2CH2CH2), 3.44 (s, Si(OCH3)3), 4.63 (d, CHC(CH3)2SH), 6.99 (d, CHNHCOCH3), 7.70 (t, CH2NHCOCH). 13C NMR (CDCl3) δ □6.59 (SiCH2), 22.42 and 22.97 (CH(CH3)2SH), 28.64 (NHCOCH3), 30.80 (SiCH2CH2), 41.93 (CHC(CH3)2SH), 46.23 (SiCH2CH2CH2), 50.35 (Si(OCH3)3), 60.32 (CHC(CH3)2SH), 169.64 (CHNHCOCH3), 170.17 (CHCONH).
The preparation of tertiary thiol-based precursors was investigated for the development of biomedical devices/therapeutics with continuous and photoactivatable NO release. A NAP thiolactone was thus synthesized to design such a precursor for the synthesis of NO-releasing xerogels. Penicillamine was reacted in the presence of acetic anhydride to generate the NAP thiolactone in situ. After characterization by 1H and 13CNMR, the NAP thiolactone was directly coupled with APTMS to result in a tertiary thiol-bearing silane, referred to as NAPTMS (see
Ratios of mercaptosilane and alkoxysilane (25-85 mol % MPTMS, balance TMOS or TEOS) were added either as a bolus injection or dropwise via a Kent Scientific Genie Plus syringe pump at a flow rate of 0.25-3.0 mL/min through an 18.5 gauge needle to a solution of ethanol, water, and ammonium hydroxide. Solution was stirred for 2 h at room temperature, collected via centrifugation at 4500 rpm (10 mins), washed twice with 40 mL EtOH, recollected, and dried overnight at ambient conditions.
Our initial attempt to synthesize thiol-containing silica particles was based on a bolus injection of 3-mercaptopropyltrimethoxysilane (MPTMS) and alkoxysilane into EtOH/NH4OH solution, The resulting concentrations of ammonia, water and total silane were 3.3, 8.0, and 0.2 M, respectively. Tetramethoxysilane (TMOS) proved to be a sufficient backbone silane for co-condensation with MPTMS as their combination (at various mole percentages) resulted in the formation of a white precipitate. (˜300 mg yield).
As indicated by solution turbidity, a marked increase in reaction time was observed upon increasing the concentration of MPTMS up to 85 mol %. At this concentration, the time to form a visible product after combining the silanes was roughly 15 min. Product formation at MPTMS concentrations >85 mol % was not observed. The inability to form particles at greater MPTMS concentrations may be attributed to the disparate hydrolysis rates between the silanes, suggesting that co-condensation requires a minimum concentration of the more readily hydrolyzable silane (i.e., TMOS) to initiate particle growth.
Materials synthesized via the co-condensation of MPTMS and tetraethoxysilane (TEOS) formed only in the concentration range of 75-85 mol % MPTMS. In contrast to the TMOS system, products with lower concentrations of MPTMS (e.g., 25 mol %) did not form using TEOS as a backbone, even at prolonged reaction times (up to 48 h).
Another thiol-functionalized monomer, 3-mercaptopropylmethyldimethoxysilane (MPMDMS), was also investigated. Unfortunately, the product yield (˜5 mg) formed using MPMDMS with either TMOS or TEOS was significantly lower than MPTMS. The substitution of one of the hydrolyzable methoxy groups with a nonhydrolyzable methyl linkage in MPMDMS (vs. MPTMS) appears to decrease the resulting hydrolysis rate under basic conditions, possibly due to the inductive effect of electron density donation to the Si atom. As a result, the reaction with hydroxide anion to hydrolyze the silane may be inhibited. Particle formation may even be further limited as each MPMDMS molecule is capable of forming only two siloxane bridges. Consequently, particle formation using MPMDMS was unsuccessful.
Solid-state cross polarization/magic angle spinning (CP/MAS) 29Si (71.548 MHz frequency) nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker 360 MHz DMX spectrometer (Billerica, Mass.). Particles were packed into 4 mm rotors and spun at 8.0 kHz. Spectra were collected at 5000 scans with the determination of chemical shifts in parts per million relative to an external TMS standard. Nitric oxide release was measured in real time (1 sec intervals) using 5 a Sievers NOATM 280i Chemiluminescence Nitric Oxide Analyzer (NOA) (Boulder, Colo.). Calibration of the NOA was performed with both air passed through a Sievers NO zero filter and 26.39 ppm NO gas (balance N2). Nitric oxide-releasing particles were immersed in 25 mL of deoxygenated solution and sparged with an 80 mL min−1 N2 stream. Additional N2 was supplied to the reaction flask to match the collection rate of the NOA at 200 mL min−1.
Temperature control was maintained using a water bath at 37° C. Thermal and photo-initiated NO release were studied by conducting the experiments in 500 μM DTPA (pH 7.4 PBS) to chelate trace copper and illuminating the sample flask with 60, 100, and 200 W incandescent bulbs, respectively. Copper-initiated NO release was studied by adding the particles to 25 mL of 10 or 25 μM CuBr2(aq). The NOA sample flask was shielded from light with aluminum foil for experiments where light was not the intended initiator of NO release. Particle size was determined using a Zetasizer Nano ZS Particle Size and Zeta Potential Dynamic Light Scattering (DLS) Instrument (Malvern, UK). Samples were suspended in PBS at a concentration of 1 mg mL-1 and sonicated for 15 min prior to analysis. Scanning electron micrographs were recorded on a Hitachi S-4700 Scanning Electron Microscope (Pleasanton, Calif.).
To confirm the incorporation of mercaptosilane within the silica network and compare various compositions, solid-state 29Si cross polarization/magic angle spinning nuclear magnetic resonance (CP/MAS NMR) was used to characterize the MPTMS/TMOS products as a function of MPTMS concentration: Silicon atoms of tetraalkoxysilanes appear in the NMR spectra as Qn bands while those of organotrialkoxysilanes appear as Tn bands. In both cases, n denotes the number of siloxane bonds attached to the Si atom. The greater number of siloxane bonds to the Si atom, the further the NMR band shifts upfield.
Sulfur weight percent of each composition was determined using elemental analysis and further corroborated the covalent incorporation of the mercaptosilane. The weight percent of sulfur in the silica was 4.92, 7.11, 11.67, 13.56 and 17.30 for the 25, 40, 60, 75 and 85 mol % MPTMS (balance TMOS) compositions, respectively. The TEOS-based particles were found to have sulfur weight percents of 16.15 and 19.34 for 75 and 85 mol % MPTMS, respectively. As expected, the weight percent of sulfur increased linearly with increasing MPTMS concentration in the initial solution.
Dynamic light scattering (DLS) measurements indicated that the sample was too polydisperse to accurately measure the particle size. Scanning electron micrographs (SEMs) further indicated that the thiol-containing silica was polydisperse and exhibited nonspherical morphology more indicative of colloidal silica than individual particles. (data not shown).
We systematically varied synthetic parameters (i.e., water, ammonia, and silane concentrations) to tune the resulting particle morphology and achieve a more spherical shape. The composition of 25 mol % MPTMS (balance TMOS) was chosen as the model system for comparison due to minimal organic character.
For MPTMS particles, we found that increasing the water content from 8.0 to 16.2 M promoted the formation of spherical particles and prevented aggregation/fusion. Lower ammonia concentrations were shown to result in particles that lacked spherical shape and aggregated. Thus, we discovered that the ratio of water and ammonia to silane was a critical factor during particle synthesis. Upon considering all the data, we determined that the most spherical and monodisperse particles were the 25 mol % MPTMS (balance TMOS) particles were formed using 5.5 M ammonia, 0.1 M total silane, and 16.2 M water. Of note, the product yield (˜70 mg) with this synthesis was lower than that obtained for the polydisperse colloidal silica. The decreased yield was due to the 4-fold decrease in the silane concentration used in the optimized synthesis.
Next, the concentration of MPTMS in the solution was increased to enhance the degree of thiol functionality and potential NO storage of the particles.
As with the polydisperse colloidal silica system, the formation of particles was not observed for 25-60 mol % MPTMS (balance TEOS). Only 75 and 85 mol % MPTMS concentrations yielded particles with TEOS, illustrating how disparities in hydrolysis and condensation kinetics adversely affect and hinder particle formation. The 75 mol % MPTMS (balance TEOS) particles formed in a narrow size distribution and exhibited spherical morphologies (
To remedy the bimodal size distribution that was observed for certain MPTMS compositions, we evaluated the effect of a silane feed rate of 0.5 mL min−1 on particle morphologies throughout the range of compositions (
Additionally, the product yield increased to ˜170 mg for these two compositions and can be attributed to the greater concentration of the larger MPTMS in the particles. Unfortunately, the semi-batch process proved problematic for 60, 75, and 85 mol % MPTMS (balance TMOS) particles. As shown in
We then attempted to decrease the size of the particles to improve particle monodispersity. The 75 mol % MPTMS (balance TEOS) particles were chosen as a model system to examine the effect of the water concentration on particle size and morphology. As shown in
The appropriate water concentrations (32.5 and 24.9 M) were next used to tune particle size and reduce the bimodal distribution characteristic of the 60, 75, and 85 mol % MPTMS (balance TMOS) particles. As shown in
The TEOS-based counterpart to this system behaved similarly by yielding only discrete particles (506±77 nm) when synthesized with the higher water concentration. At lower water amounts, the formation of aggregated particles was noted. The trend of decreasing particle yield with increasing water content that was observed for the 75 mol % MPTMS (balance TEOS) composition was mirrored for all other compositions evaluated. The yields for the 75 mol % (balance TMOS) particles decreased from ˜120 to 60 mg upon increasing the water content from 24.9 to 32.5 M. Likewise, the 25 mol % MPTMS (balance TMOS) particle yield decreased from ˜90 to 20 mg while the 40 mol % MPTMS system exhibited a decrease from ˜50 to 9 mg upon increasing the water concentration from 16.2 to 24.9 M. The yields for both 85 mol % MPTMS compositions (i.e, TMOS and TEOS balance) at a water concentration of 32.5 M were ˜160 mg. Perhaps of greatest significance, the elevated water concentrations used to synthesize the thiol-modified particles successfully resolved the bimodal nature of certain compositions not resolvable using a semi-batch process alone. Of note, 60 mol % MPTMS (balance TMOS) was the only composition that consistently yielded particles of a bimodal nature. Increasing the water content regardless of addition method (bolus vs. semi-batch) resulted in a highly-fused silica network.
Particle sizes were also measured by DLS to corroborate particle monodispersity and size measured using SEM. As shown in Table 1, the DLS measurements were in agreement with the sizes calculated from the SEM images. The slightly increased average diameters observed with DLS may be attributed to particle hydration (DLS measurements conducted in solution). Like SEM, the DLS measurements indicated a narrow size distribution, as evidenced by low polydispersity indices for each composition.
aSize calculated from scanning electron micrographs of n = 120 particles
bSizes acquired from dynamic light scattering measurements in pH 7.4 PBS for n = 3 syntheses
cEthanol used as dispersant
Of note, PBS was used as a dispersant for compositions with a large concentration of MPTMS. However, smaller particles with a large degree of inorganic character (i.e., ≦40 mol % MPTMS) rapidly aggregated in this dispersant and caused erratic DLS measurements. This aggregation may be attributed to a large surface density of protonated silanol groups leading to unfavorable particle interaction. While basic conditions resulted in inconsistent DLS measurements due to particle dissolution, ethanol was a viable alternative dispersant as evidenced by the correlation between DLS and SEM measurements.
Elemental analysis was used to characterize the composition of the particles. As expected, the weight percentages of sulfur in the particles increased accordingly with the MPTMS mol % used to make the particles indicating incorporation of the thiol functionality (Table 2).
aAverage weight percents are calculated from n = 3 syntheses
bWeight percent was less than instrument limit of detection
Syntheses promoting the formation of discrete, spherical particles tended to be preferentially derived from one precursor as evidenced by a large gap in the transition from 40 to 75 mol % MPTMS (wt % 3.08±2.57 and 15.62±1.90, respectively). These values were in marked contrast to the sulfur wt % of the colloidal silica. Although the increased sulfur wt % were more linearly proportional for the colloidal silica, the lack of discrete, spherical particles was not ideal. The comparison of the two systems (colloidal vs. discrete particles) and syntheses reveals that a balance exists between silane incorporation and certain design criteria.
Procedure for 25% NAPTMS Balance TMOS/TEOS:
Size Characterization:
Thiols within the particles were nitrosated via reaction with nitrous acid. 12 Particles (˜200 mg) were first added to 4 mL methanol (MeOH). While stirring, 2 mL of hydrochloric acid (5 M) was added to the suspension. A 2 mL aqueous solution containing sodium nitrite (2× molar excess to thiol) and DTPA (500 μM) was then added to the particle suspension, and the mixture stirred for 2 h in the dark and on ice. Particles were collected by centrifugation at 4500 rpm (5 min), washed with 40 mL chilled 500 μM DTPA(aq), recollected, washed with 40 mL chilled MeOH, recollected, and vacuum dried for 30 min while shielded from light. Particles were stored at −20° C. in vacuo until further study.
The MPTMS-modified particles were nitrosated to enable NO storage and release. Briefly, the particles were treated with acidified sodium nitrite, generating nitrous acid, a nitrosating agent that reacts with thiols to form RSNOs (see Eq 1).
RSH+HNO2RSNO+H2O (1)
Since S-nitrosothiols prepared from primary thiols absorb light at 330-350 and 550-600 nm, successful RSNO formation was confirmed by the resulting red color of the particles after nitrosation. Furthermore, the intensity of the color increased with MPTMS mol % indicating greater RSNO formation.
As widely known, S-nitrosothiols decompose via a multitude of pathways (
To assess the NO storage and release, RSNO-modified particles (˜2 mg) were added to 500 μM DTPA (pH 7.4 PBS) at a temperature of 0° C., while measuring the ensuing NO release as a function of photolytic decomposition. As shown in
Due to the rapid kinetics of the photo-initiated decomposition, total NO storage of the particles was assessed by exposing the particles to 200 W of broadband light. Indeed, >95% of the NO stored was released after 5 h of irradiation at 200 W. As given in Table 3, the total NO released from the particles ranged from 0.09-4.39 μmol mg−1. These levels of NO storage are an order of magnitude larger than previously reported RSNO-modified silica particles. Using the average sulfur weight percents in conjunction with the average NO storage values, the percent conversion of thiol to RSNO for the different particle compositions was calculated to be 58-78% for the 75 and 85 mol % MPTMS/TMOS and MPTMS/TEOS systems. The 25 and 40 mol % MPTMS particles were found to have lower thiol to RSNO conversions (54-63%).
aAverages are calculated from n = 3 syntheses and after 5 h of 200 W irradiation
The effect of copper on NO release was investigated as a function of copper concentration. These assays were performed using Cu(II) via CuBr2 due to the insolubility of Cu(I) compounds in aqueous solutions. As expected, the NO release from the RSNO-modified particles correlated with the copper concentration (
The use of RSNO-modified particles for biomedical application likely necessitates an NO release trigger other than light or large concentrations of free copper ions. We thus evaluated NO release from the particles via thermal degradation at 37° C. using 75 mol % MPTMS (balance TEOS, 718.0±51.7 nm) as a model system. Particles were introduced into 500 μM DTPA (pH 7.4 PBS), maintained at 37° C. and shielded from external light while monitoring NO release over 48 h (Table 4). Under these conditions, the particles released a total of 1.17 μmol NO mg−1 with a corresponding half life of 2.95 h. When compared to the total amount released after 5 h using 200 W irradiation (3.15 μmol mg−1, Table 3), the discrepancy may be attributed to inability to measure NO at low levels beyond 48 h and/or loss of NO through its reaction with oxygen present in the soak solutions. As evident by a pink hue, the particles still contained a portion of their NO payload even after 48 h of release.
aAverages are calculated from n = 3 syntheses
For each particle composition, approximately 3 mg of particles were added to the collection flask containing PBS (500 μM DTPA) and the NO release monitored over 75 min. The NO storage and release characteristics are shown in Table 5.
The NO storage and release characteristics of the 25% NAPTMS sample while under irradiation were also investigated. Using 200 W illumination, and 0.3 m distance, the results are shown in Table 6.
The results shown in Tables 5 and 6 shown that NO stability of the particles can be significantly increased by using a tertiary nitrosothiol-functionalized silica particles.
Experiment 8A: Nitrosated Particles No Sonication
SEM images of the particles formed in Example 7A are provided in
In the drawings and specification, there have been disclosed embodiments of the invention and, although specific terms are employed, they are used in a generic and descriptive sense only and not for purposes of limitation, the scope of the invention being set forth in the following claims.
This application is a continuation under 35 U.S.C. §111(a) of PCT Application No. PCT/US2012/026960, filed on Feb. 28, 2012, which claims the benefit, under 35 U.S.C. §119, of U.S. Provisional Application Ser. No. 61/447,368, filed Feb. 28, 2011, and U.S. Provisional Application No. 61/565,694, filed Dec. 1, 2011, the disclosure of each of which is hereby incorporated by reference herein in its entirety.
The present invention was funded in part by government support under grant number 5-R01-EB000708 from the National Institutes of Health. The United States Government has certain rights in this invention.
Number | Name | Date | Kind |
---|---|---|---|
4507466 | Tomalia et al. | Mar 1985 | A |
4558120 | Tomalia et al. | Dec 1985 | A |
4568737 | Tomalia et al. | Feb 1986 | A |
4587329 | Tomalia et al. | May 1986 | A |
4631337 | Tomalia et al. | Dec 1986 | A |
4694064 | Tomalia et al. | Sep 1987 | A |
4713975 | Tomalia et al. | Dec 1987 | A |
4737550 | Tomalia | Apr 1988 | A |
4857599 | Tomalia et al. | Aug 1989 | A |
4871779 | Killat et al. | Oct 1989 | A |
4985023 | Blank et al. | Jan 1991 | A |
4990338 | Blank et al. | Feb 1991 | A |
5035892 | Blank et al. | Jul 1991 | A |
5045322 | Blank et al. | Sep 1991 | A |
5061487 | Blank et al. | Oct 1991 | A |
5079004 | Blank et al. | Jan 1992 | A |
5380758 | Stamler et al. | Jan 1995 | A |
5405919 | Keefer et al. | Apr 1995 | A |
5418301 | Hult et al. | May 1995 | A |
5428070 | Cooke et al. | Jun 1995 | A |
5504117 | Gorfine | Apr 1996 | A |
5519020 | Smith et al. | May 1996 | A |
5525357 | Keefer et al. | Jun 1996 | A |
5574068 | Stamler et al. | Nov 1996 | A |
5593876 | Stamler et al. | Jan 1997 | A |
5599984 | Bianchi et al. | Feb 1997 | A |
5629322 | Guthikonda et al. | May 1997 | A |
5632981 | Saavedra et al. | May 1997 | A |
5650442 | Mitchell et al. | Jul 1997 | A |
5650447 | Keefer et al. | Jul 1997 | A |
5665077 | Rosen et al. | Sep 1997 | A |
5676963 | Keefer et al. | Oct 1997 | A |
5691423 | Smith et al. | Nov 1997 | A |
5693676 | Gorfine | Dec 1997 | A |
5700830 | Korthuis et al. | Dec 1997 | A |
5718892 | Keefer et al. | Feb 1998 | A |
5726156 | Girten et al. | Mar 1998 | A |
5750573 | Bianchi et al. | May 1998 | A |
5753684 | Bianchi et al. | May 1998 | A |
5760001 | Girten et al. | Jun 1998 | A |
5770645 | Stamler et al. | Jun 1998 | A |
5786332 | Girten et al. | Jul 1998 | A |
5789447 | Wink, Jr. et al. | Aug 1998 | A |
5797887 | Rosen et al. | Aug 1998 | A |
5810010 | Anbar | Sep 1998 | A |
5814666 | Green et al. | Sep 1998 | A |
5814667 | Mitchell et al. | Sep 1998 | A |
5821261 | Durette et al. | Oct 1998 | A |
5837736 | Mitchell et al. | Nov 1998 | A |
5840759 | Mitchell et al. | Nov 1998 | A |
5849794 | Bianchi et al. | Dec 1998 | A |
5852058 | Cooke et al. | Dec 1998 | A |
5854289 | Bianchi et al. | Dec 1998 | A |
5859062 | Bianchi et al. | Jan 1999 | A |
5861168 | Cooke et al. | Jan 1999 | A |
5863890 | Stamler et al. | Jan 1999 | A |
5891459 | Cooke et al. | Apr 1999 | A |
5891472 | Russell | Apr 1999 | A |
5910316 | Keefer et al. | Jun 1999 | A |
5932538 | Garvey et al. | Aug 1999 | A |
5958427 | Salzman et al. | Sep 1999 | A |
5961466 | Anbar | Oct 1999 | A |
5962520 | Smith et al. | Oct 1999 | A |
5994294 | Garvey et al. | Nov 1999 | A |
5994444 | Trescony et al. | Nov 1999 | A |
5999843 | Anbar | Dec 1999 | A |
6008255 | Bianchi et al. | Dec 1999 | A |
6022900 | Bianchi et al. | Feb 2000 | A |
6035225 | Anbar | Mar 2000 | A |
6043358 | Caldwell et al. | Mar 2000 | A |
6045827 | Russell | Apr 2000 | A |
6070928 | Campbell | Jun 2000 | A |
6087479 | Stamler et al. | Jul 2000 | A |
6103275 | Seitz et al. | Aug 2000 | A |
6110453 | Keefer et al. | Aug 2000 | A |
6143037 | Goldstein et al. | Nov 2000 | A |
6147068 | Smith et al. | Nov 2000 | A |
6151522 | Alfano et al. | Nov 2000 | A |
6160021 | Lerner et al. | Dec 2000 | A |
6171232 | Papandreou et al. | Jan 2001 | B1 |
6174539 | Stamler et al. | Jan 2001 | B1 |
6180082 | Woltering et al. | Jan 2001 | B1 |
6180676 | Bianchi et al. | Jan 2001 | B1 |
6190704 | Murrell | Feb 2001 | B1 |
6200558 | Saavedra et al. | Mar 2001 | B1 |
6207855 | Toone et al. | Mar 2001 | B1 |
6218016 | Tedeschi et al. | Apr 2001 | B1 |
6232336 | Hrabie et al. | May 2001 | B1 |
6232434 | Stamler et al. | May 2001 | B1 |
6238683 | Burnett et al. | May 2001 | B1 |
6248787 | Bianchi et al. | Jun 2001 | B1 |
6255277 | Stamler et al. | Jul 2001 | B1 |
6261594 | Smith et al. | Jul 2001 | B1 |
6270779 | Fitzhugh et al. | Aug 2001 | B1 |
6287601 | Russell | Sep 2001 | B1 |
6290981 | Keefer et al. | Sep 2001 | B1 |
6291424 | Stamler et al. | Sep 2001 | B1 |
6294517 | Garvey et al. | Sep 2001 | B1 |
6299980 | Shah et al. | Oct 2001 | B1 |
6323211 | Garvey et al. | Nov 2001 | B1 |
6350467 | Demopoulos et al. | Feb 2002 | B1 |
6352709 | Stamler et al. | Mar 2002 | B1 |
6358536 | Thomas | Mar 2002 | B1 |
6359167 | Toone et al. | Mar 2002 | B2 |
6359182 | Stamler et al. | Mar 2002 | B1 |
6369071 | Haj-Yehia | Apr 2002 | B1 |
6372733 | Caldwell et al. | Apr 2002 | B1 |
6377321 | Khan et al. | Apr 2002 | B1 |
6379660 | Saavedra et al. | Apr 2002 | B1 |
6379691 | Tedeschi et al. | Apr 2002 | B1 |
6391895 | Towart et al. | May 2002 | B1 |
6403759 | Stamler et al. | Jun 2002 | B2 |
6410622 | Endres | Jun 2002 | B1 |
6417162 | Garvey et al. | Jul 2002 | B1 |
6432077 | Stenzler | Aug 2002 | B1 |
6433182 | Garvey et al. | Aug 2002 | B1 |
6436975 | Del Soldato | Aug 2002 | B1 |
6441254 | Dobert | Aug 2002 | B1 |
6448267 | Anggard et al. | Sep 2002 | B1 |
6451337 | Smith et al. | Sep 2002 | B1 |
6455542 | Anggard et al. | Sep 2002 | B1 |
6469065 | Garvey et al. | Oct 2002 | B1 |
6471978 | Stamler et al. | Oct 2002 | B1 |
6472390 | Stamler et al. | Oct 2002 | B1 |
6488951 | Toone et al. | Dec 2002 | B2 |
6492405 | Haj-Yehia | Dec 2002 | B2 |
6511991 | Hrabie et al. | Jan 2003 | B2 |
6514934 | Garvey et al. | Feb 2003 | B1 |
6538033 | Bing | Mar 2003 | B2 |
6560478 | Alfano et al. | May 2003 | B1 |
6562344 | Stamler et al. | May 2003 | B1 |
6562785 | Shapiro | May 2003 | B1 |
6583113 | Stamler et al. | Jun 2003 | B2 |
6583311 | Toone et al. | Jun 2003 | B2 |
6605447 | Weiss et al. | Aug 2003 | B2 |
6610660 | Saavedra et al. | Aug 2003 | B1 |
6627602 | Stamler et al. | Sep 2003 | B2 |
6642208 | Cooke et al. | Nov 2003 | B2 |
6642260 | Haj-Yehia | Nov 2003 | B2 |
6645518 | Tedeschi et al. | Nov 2003 | B2 |
6646006 | Cooke et al. | Nov 2003 | B2 |
6656217 | Herzog, Jr. et al. | Dec 2003 | B1 |
6673338 | Arnold et al. | Jan 2004 | B1 |
6673891 | Stamler et al. | Jan 2004 | B2 |
6699846 | Elliott et al. | Mar 2004 | B2 |
6703046 | Fitzhugh et al. | Mar 2004 | B2 |
6706274 | Hermann et al. | Mar 2004 | B2 |
6709681 | Benjamin et al. | Mar 2004 | B2 |
6723703 | Gaston et al. | Apr 2004 | B2 |
6737447 | Smith et al. | May 2004 | B1 |
6747062 | Murrell | Jun 2004 | B2 |
6750254 | Hrabie et al. | Jun 2004 | B2 |
6758214 | Fine et al. | Jul 2004 | B2 |
6759430 | Anggard et al. | Jul 2004 | B2 |
6780849 | Herrmann et al. | Aug 2004 | B2 |
6793644 | Stenzler | Sep 2004 | B2 |
6796966 | Thomas | Sep 2004 | B2 |
6841166 | Zhang et al. | Jan 2005 | B1 |
6855366 | Smith et al. | Feb 2005 | B2 |
6875840 | Stamler et al. | Apr 2005 | B2 |
6887485 | Fitzhugh et al. | May 2005 | B2 |
6887994 | Stamler et al. | May 2005 | B2 |
6894073 | Lee et al. | May 2005 | B2 |
6896899 | Demopolos et al. | May 2005 | B2 |
6897218 | Casella et al. | May 2005 | B2 |
6911433 | Saavedra et al. | Jun 2005 | B2 |
6911478 | Hrabie et al. | Jun 2005 | B2 |
6946484 | Adams et al. | Sep 2005 | B2 |
6949530 | Hrabie et al. | Sep 2005 | B2 |
6951902 | McDonald et al. | Oct 2005 | B2 |
6964984 | Stamler et al. | Nov 2005 | B2 |
6974801 | Honda et al. | Dec 2005 | B2 |
7012098 | Manning et al. | Mar 2006 | B2 |
7015347 | Toone et al. | Mar 2006 | B2 |
7025869 | Fine et al. | Apr 2006 | B2 |
7030238 | Stamler et al. | Apr 2006 | B2 |
7033999 | Stamler et al. | Apr 2006 | B2 |
7040313 | Fine et al. | May 2006 | B2 |
7048951 | Seitz et al. | May 2006 | B1 |
7049308 | Stamler et al. | May 2006 | B2 |
7052711 | West et al. | May 2006 | B2 |
7070798 | Michal et al. | Jul 2006 | B1 |
7081524 | Saavedra et al. | Jul 2006 | B2 |
7087588 | Del Soldato | Aug 2006 | B2 |
7087709 | Stamler et al. | Aug 2006 | B2 |
7122018 | Stenzler et al. | Oct 2006 | B2 |
7122027 | Trescony et al. | Oct 2006 | B2 |
7122529 | Ruane et al. | Oct 2006 | B2 |
7128904 | Batchelor et al. | Oct 2006 | B2 |
7135189 | Knapp | Nov 2006 | B2 |
7135498 | Chopp et al. | Nov 2006 | B1 |
7157500 | Stamler et al. | Jan 2007 | B2 |
7169809 | Berthelette et al. | Jan 2007 | B2 |
7176237 | Honda et al. | Feb 2007 | B2 |
7179475 | Burnett et al. | Feb 2007 | B1 |
7189761 | Gorfine | Mar 2007 | B2 |
7199154 | Berthelette et al. | Apr 2007 | B2 |
7204980 | Clark | Apr 2007 | B2 |
7226586 | Fitzhugh et al. | Jun 2007 | B2 |
7234079 | Cheng | Jun 2007 | B2 |
7259250 | Stamler et al. | Aug 2007 | B2 |
7279176 | West et al. | Oct 2007 | B1 |
7282519 | Garvey et al. | Oct 2007 | B2 |
7314857 | Madhyastha | Jan 2008 | B2 |
7335383 | Meyerhoff et al. | Feb 2008 | B2 |
7345053 | Garvey | Mar 2008 | B2 |
7348319 | Hrabie et al. | Mar 2008 | B2 |
7364585 | Weber | Apr 2008 | B2 |
7396829 | Garvey et al. | Jul 2008 | B2 |
7417109 | Stamler et al. | Aug 2008 | B2 |
7425218 | Keefer et al. | Sep 2008 | B2 |
7432301 | Gaston et al. | Oct 2008 | B2 |
7452916 | Cooke | Nov 2008 | B2 |
7468435 | Waterhouse et al. | Dec 2008 | B2 |
7485324 | Miller et al. | Feb 2009 | B2 |
7520866 | Stenzler et al. | Apr 2009 | B2 |
7531164 | Daaka et al. | May 2009 | B2 |
7569559 | Arnold et al. | Aug 2009 | B2 |
7582623 | Mascharak | Sep 2009 | B2 |
7595313 | Garvey et al. | Sep 2009 | B2 |
7622501 | Dufresne et al. | Nov 2009 | B2 |
7622502 | Berthelette et al. | Nov 2009 | B2 |
7645748 | Orchansky et al. | Jan 2010 | B2 |
7645749 | Orchansky et al. | Jan 2010 | B2 |
7651697 | West et al. | Jan 2010 | B2 |
7655423 | Chopp et al. | Feb 2010 | B2 |
7678391 | Graham et al. | Mar 2010 | B2 |
7678830 | Honda et al. | Mar 2010 | B2 |
7696247 | Herrmann et al. | Apr 2010 | B2 |
7745656 | Toone et al. | Jun 2010 | B2 |
7763283 | Batchelor et al. | Jul 2010 | B2 |
7785616 | Stamler et al. | Aug 2010 | B2 |
7795286 | Lucet-Levannier | Sep 2010 | B2 |
7799335 | Herrmann et al. | Sep 2010 | B2 |
7807716 | Farber | Oct 2010 | B2 |
7811600 | Cheng et al. | Oct 2010 | B2 |
7820284 | Terry | Oct 2010 | B2 |
7829553 | Arnold et al. | Nov 2010 | B2 |
7838023 | Garvey et al. | Nov 2010 | B2 |
7846400 | Hyde et al. | Dec 2010 | B2 |
7862598 | Hyde et al. | Jan 2011 | B2 |
7892198 | Stenzler | Feb 2011 | B2 |
7897399 | Hyde et al. | Mar 2011 | B2 |
7928079 | Hrabie et al. | Apr 2011 | B2 |
7928096 | Waterhouse et al. | Apr 2011 | B2 |
7947299 | Knapp | May 2011 | B2 |
7972137 | Rosen | Jul 2011 | B2 |
7975699 | Hyde et al. | Jul 2011 | B2 |
8003811 | Almirante | Aug 2011 | B2 |
8017074 | Arnold | Sep 2011 | B2 |
8021679 | Chen | Sep 2011 | B2 |
8034384 | Meyerhoff | Oct 2011 | B2 |
8043246 | Av-Gay et al. | Oct 2011 | B2 |
20010012851 | Lundy et al. | Aug 2001 | A1 |
20010025057 | Gorfine | Sep 2001 | A1 |
20010038832 | Bonavida et al. | Nov 2001 | A1 |
20010053772 | Bonavida et al. | Dec 2001 | A1 |
20020028851 | Bianchi et al. | Mar 2002 | A1 |
20020049157 | Wu et al. | Apr 2002 | A1 |
20020061879 | Garvey et al. | May 2002 | A1 |
20020068365 | Kuhrts | Jun 2002 | A1 |
20020090401 | Tucker et al. | Jul 2002 | A1 |
20020115586 | Enikolopov | Aug 2002 | A1 |
20020132234 | Moskowitz | Sep 2002 | A1 |
20020136763 | Demopoulos et al. | Sep 2002 | A1 |
20020138051 | Hole et al. | Sep 2002 | A1 |
20020143007 | Garvey et al. | Oct 2002 | A1 |
20020143062 | Lopez-Berestein et al. | Oct 2002 | A1 |
20020155174 | Benjamin et al. | Oct 2002 | A1 |
20020161042 | Gorfine | Oct 2002 | A1 |
20030027844 | Soldato | Feb 2003 | A1 |
20030039697 | Zhao et al. | Feb 2003 | A1 |
20030050305 | Tejada | Mar 2003 | A1 |
20030072783 | Stamler et al. | Apr 2003 | A1 |
20030093143 | Zhao et al. | May 2003 | A1 |
20030134779 | Diarra et al. | Jul 2003 | A1 |
20030170674 | Moskowitz | Sep 2003 | A1 |
20030203915 | Fang et al. | Oct 2003 | A1 |
20030205234 | Bardach et al. | Nov 2003 | A1 |
20040009238 | Miller et al. | Jan 2004 | A1 |
20040013747 | Tucker et al. | Jan 2004 | A1 |
20040033480 | Wong | Feb 2004 | A1 |
20040037836 | Stamler et al. | Feb 2004 | A1 |
20040037897 | Benjamin et al. | Feb 2004 | A1 |
20040043068 | Tedeschi et al. | Mar 2004 | A1 |
20040076582 | Dimatteo et al. | Apr 2004 | A1 |
20040082659 | Cooke et al. | Apr 2004 | A1 |
20040105898 | Benjamin et al. | Jun 2004 | A1 |
20040110691 | Stamler | Jun 2004 | A1 |
20040131703 | Bach et al. | Jul 2004 | A1 |
20040143010 | Esteve-Soler et al. | Jul 2004 | A1 |
20040147598 | Haj-Yehia | Jul 2004 | A1 |
20040157936 | Burnett et al. | Aug 2004 | A1 |
20040228889 | Cals-Grierson | Nov 2004 | A1 |
20040254419 | Wang et al. | Dec 2004 | A1 |
20040265244 | Rosen | Dec 2004 | A1 |
20050036949 | Tucker et al. | Feb 2005 | A1 |
20050037093 | Benjamin | Feb 2005 | A1 |
20050054714 | Munoz et al. | Mar 2005 | A1 |
20050065161 | Garvey et al. | Mar 2005 | A1 |
20050069595 | Chen et al. | Mar 2005 | A1 |
20050074506 | Natan et al. | Apr 2005 | A1 |
20050079132 | Wang et al. | Apr 2005 | A1 |
20050080021 | Tucker et al. | Apr 2005 | A1 |
20050080024 | Tucker et al. | Apr 2005 | A1 |
20050131064 | Gaston et al. | Jun 2005 | A1 |
20050142217 | Adams et al. | Jun 2005 | A1 |
20050142218 | Tucker et al. | Jun 2005 | A1 |
20050152891 | Toone et al. | Jul 2005 | A1 |
20050165452 | Sigg et al. | Jul 2005 | A1 |
20050171066 | Shami | Aug 2005 | A1 |
20050171199 | Murrell | Aug 2005 | A1 |
20050187222 | Garvey et al. | Aug 2005 | A1 |
20050220838 | Zhao et al. | Oct 2005 | A1 |
20050249818 | Sawan et al. | Nov 2005 | A1 |
20050265958 | West et al. | Dec 2005 | A1 |
20050281867 | Kahn et al. | Dec 2005 | A1 |
20060008529 | Meyerhoff et al. | Jan 2006 | A1 |
20060009431 | Earl et al. | Jan 2006 | A1 |
20060035854 | Goldstein et al. | Feb 2006 | A1 |
20060039950 | Zhou et al. | Feb 2006 | A1 |
20060058363 | Wang et al. | Mar 2006 | A1 |
20060067909 | West et al. | Mar 2006 | A1 |
20060095120 | Hermann | May 2006 | A1 |
20060100159 | Stamler et al. | May 2006 | A1 |
20060142183 | Diarra et al. | Jun 2006 | A1 |
20060147553 | Miller et al. | Jul 2006 | A1 |
20060147904 | Wong | Jul 2006 | A1 |
20060159726 | Shell | Jul 2006 | A1 |
20060172018 | Fine et al. | Aug 2006 | A1 |
20060198831 | Stamler et al. | Sep 2006 | A1 |
20060211601 | Stamler et al. | Sep 2006 | A1 |
20060269620 | Morris et al. | Nov 2006 | A1 |
20060286158 | Calvert Murrell et al. | Dec 2006 | A1 |
20060286159 | Calvert Murrell et al. | Dec 2006 | A1 |
20070003538 | Madhyastha | Jan 2007 | A1 |
20070014686 | Arnold et al. | Jan 2007 | A1 |
20070014733 | O'Donnell et al. | Jan 2007 | A1 |
20070014828 | Fitzhugh et al. | Jan 2007 | A1 |
20070037821 | Garvey et al. | Feb 2007 | A1 |
20070048344 | Yahiaoui et al. | Mar 2007 | A1 |
20070053952 | Chen et al. | Mar 2007 | A1 |
20070053955 | Larson et al. | Mar 2007 | A1 |
20070053966 | Ang et al. | Mar 2007 | A1 |
20070059351 | Murrell et al. | Mar 2007 | A1 |
20070086954 | Miller | Apr 2007 | A1 |
20070087025 | Fitzhugh et al. | Apr 2007 | A1 |
20070088345 | Larson et al. | Apr 2007 | A1 |
20070089739 | Fine et al. | Apr 2007 | A1 |
20070116785 | Miller | May 2007 | A1 |
20070129690 | Rosenblatt et al. | Jun 2007 | A1 |
20070148136 | Whitlock | Jun 2007 | A1 |
20070154570 | Miller et al. | Jul 2007 | A1 |
20070166227 | Liu et al. | Jul 2007 | A1 |
20070172469 | Clark | Jul 2007 | A1 |
20070191377 | Worcel | Aug 2007 | A1 |
20070196327 | Kalivretenos et al. | Aug 2007 | A1 |
20070197543 | Esteve-Soler et al. | Aug 2007 | A1 |
20070202155 | Ang et al. | Aug 2007 | A1 |
20070203242 | Calton | Aug 2007 | A1 |
20070207179 | Andersen et al. | Sep 2007 | A1 |
20070219208 | Kalyanaraman et al. | Sep 2007 | A1 |
20070225250 | Brown | Sep 2007 | A1 |
20070239107 | Lundberg et al. | Oct 2007 | A1 |
20070243262 | Hurley et al. | Oct 2007 | A1 |
20070248676 | Stamler et al. | Oct 2007 | A1 |
20070264225 | Cheng et al. | Nov 2007 | A1 |
20070270348 | Kahn et al. | Nov 2007 | A1 |
20070275100 | Miller | Nov 2007 | A1 |
20080025972 | Daaka et al. | Jan 2008 | A1 |
20080039521 | Yasuda et al. | Feb 2008 | A1 |
20080045909 | Fossel | Feb 2008 | A1 |
20080069848 | Peters | Mar 2008 | A1 |
20080069863 | Peters | Mar 2008 | A1 |
20080069905 | Peters | Mar 2008 | A1 |
20080071206 | Peters | Mar 2008 | A1 |
20080089956 | Da et al. | Apr 2008 | A1 |
20080139450 | Madhyastha et al. | Jun 2008 | A1 |
20080145449 | Stamler | Jun 2008 | A1 |
20080171021 | Bach et al. | Jul 2008 | A1 |
20080171351 | Smith | Jul 2008 | A1 |
20080175881 | Ippoliti et al. | Jul 2008 | A1 |
20080182797 | Nudler et al. | Jul 2008 | A1 |
20080193385 | Maibach | Aug 2008 | A1 |
20080193566 | Miller et al. | Aug 2008 | A1 |
20080207491 | Diarra et al. | Aug 2008 | A1 |
20080207713 | Wang et al. | Aug 2008 | A1 |
20080214646 | Knaus et al. | Sep 2008 | A1 |
20080226751 | Tucker et al. | Sep 2008 | A1 |
20080241208 | Shanley et al. | Oct 2008 | A1 |
20080275093 | Garvey et al. | Nov 2008 | A1 |
20080280984 | Fossel | Nov 2008 | A1 |
20080286321 | Reneker et al. | Nov 2008 | A1 |
20080287861 | Stenzler et al. | Nov 2008 | A1 |
20080311163 | Peters | Dec 2008 | A1 |
20080317626 | Arnold et al. | Dec 2008 | A1 |
20080317679 | Tamarkin et al. | Dec 2008 | A1 |
20090004298 | Gaston et al. | Jan 2009 | A1 |
20090010989 | Peters | Jan 2009 | A1 |
20090018091 | Ellis et al. | Jan 2009 | A1 |
20090028966 | Chen et al. | Jan 2009 | A1 |
20090036491 | Tucker et al. | Feb 2009 | A1 |
20090042819 | Ellis et al. | Feb 2009 | A1 |
20090048219 | Garvey | Feb 2009 | A1 |
20090069449 | Smith et al. | Mar 2009 | A1 |
20090081279 | Jezek et al. | Mar 2009 | A1 |
20090088411 | Renzi et al. | Apr 2009 | A1 |
20090093510 | Clementi et al. | Apr 2009 | A1 |
20090098187 | Peters et al. | Apr 2009 | A1 |
20090108777 | Hyde et al. | Apr 2009 | A1 |
20090110612 | Hyde et al. | Apr 2009 | A1 |
20090110712 | Hyde et al. | Apr 2009 | A1 |
20090110933 | Hyde et al. | Apr 2009 | A1 |
20090110958 | Hyde et al. | Apr 2009 | A1 |
20090112055 | Hyde et al. | Apr 2009 | A1 |
20090112193 | Hyde et al. | Apr 2009 | A1 |
20090112197 | Hyde et al. | Apr 2009 | A1 |
20090118819 | Merz et al. | May 2009 | A1 |
20090123528 | Fossel | May 2009 | A1 |
20090131342 | Ellis | May 2009 | A1 |
20090136410 | Smith | May 2009 | A1 |
20090137683 | Yasuda et al. | May 2009 | A1 |
20090143417 | Smith et al. | Jun 2009 | A1 |
20090148482 | Peters | Jun 2009 | A1 |
20090186859 | Velázquez et al. | Jul 2009 | A1 |
20090191284 | Conoci et al. | Jul 2009 | A1 |
20090196930 | Surber et al. | Aug 2009 | A1 |
20090197964 | Summar et al. | Aug 2009 | A1 |
20090203653 | Garvey | Aug 2009 | A1 |
20090214618 | Schoenfisch et al. | Aug 2009 | A1 |
20090214624 | Smith et al. | Aug 2009 | A1 |
20090214674 | Barraud et al. | Aug 2009 | A1 |
20090215838 | Garvey et al. | Aug 2009 | A1 |
20090221536 | Fossel | Sep 2009 | A1 |
20090222088 | Chen et al. | Sep 2009 | A1 |
20090226504 | Peters | Sep 2009 | A1 |
20090232863 | Cheng et al. | Sep 2009 | A1 |
20090232868 | Chen et al. | Sep 2009 | A1 |
20090255536 | Av-Gay et al. | Oct 2009 | A1 |
20090263416 | Dawson et al. | Oct 2009 | A1 |
20090264398 | Bauer | Oct 2009 | A1 |
20090270509 | Arnold et al. | Oct 2009 | A1 |
20090287072 | Meyerhoff et al. | Nov 2009 | A1 |
20090297634 | Friedman et al. | Dec 2009 | A1 |
20090304815 | Cossu et al. | Dec 2009 | A1 |
20090317885 | Mascharak | Dec 2009 | A1 |
20100003338 | Hubbell et al. | Jan 2010 | A1 |
20100015253 | Benjamin | Jan 2010 | A1 |
20100016790 | Peters | Jan 2010 | A1 |
20100021506 | Jones | Jan 2010 | A1 |
20100040703 | Miller et al. | Feb 2010 | A1 |
20100062055 | Herrmann et al. | Mar 2010 | A1 |
20100076162 | Ameer et al. | Mar 2010 | A1 |
20100086530 | Martinov | Apr 2010 | A1 |
20100087370 | Jain et al. | Apr 2010 | A1 |
20100099729 | Almirante et al. | Apr 2010 | A1 |
20100112033 | Ganzarolli De Oliveira et al. | May 2010 | A1 |
20100112095 | Morris et al. | May 2010 | A1 |
20100129474 | Benjamin et al. | May 2010 | A1 |
20100152683 | Lindgren et al. | Jun 2010 | A1 |
20100159119 | Chen et al. | Jun 2010 | A1 |
20100166603 | Opie | Jul 2010 | A1 |
20100178319 | Lindgren et al. | Jul 2010 | A1 |
20100184992 | Toone et al. | Jul 2010 | A1 |
20100196517 | Fossel | Aug 2010 | A1 |
20100197702 | Hellberg et al. | Aug 2010 | A1 |
20100197802 | Jezek et al. | Aug 2010 | A1 |
20100209469 | Bezwada | Aug 2010 | A1 |
20100221308 | Madhyastha et al. | Sep 2010 | A1 |
20100233304 | Pan | Sep 2010 | A1 |
20100239512 | Morris et al. | Sep 2010 | A1 |
20100247611 | Balkus, Jr. et al. | Sep 2010 | A1 |
20100247680 | Szabo | Sep 2010 | A1 |
20100255062 | Kalivretenos et al. | Oct 2010 | A1 |
20100256755 | Chen et al. | Oct 2010 | A1 |
20100261930 | Honda et al. | Oct 2010 | A1 |
20100262238 | Chen et al. | Oct 2010 | A1 |
20100268149 | Av-Gay et al. | Oct 2010 | A1 |
20100276284 | Meyerhoff et al. | Nov 2010 | A1 |
20100280122 | Fossel | Nov 2010 | A1 |
20100285100 | Balkus, Jr. et al. | Nov 2010 | A1 |
20100303891 | Lee et al. | Dec 2010 | A1 |
20100311780 | Farber | Dec 2010 | A1 |
20100323036 | Fine | Dec 2010 | A1 |
20100324107 | Dos Santos et al. | Dec 2010 | A1 |
20100330582 | Nakamura | Dec 2010 | A1 |
20100331542 | Smith | Dec 2010 | A1 |
20100331968 | Morris et al. | Dec 2010 | A1 |
20110008815 | Stamler et al. | Jan 2011 | A1 |
20110033437 | Smith et al. | Feb 2011 | A1 |
20110046182 | Gilmer et al. | Feb 2011 | A1 |
20110059036 | Arnold et al. | Mar 2011 | A1 |
20110059189 | Cisneros | Mar 2011 | A1 |
20110065783 | O'Donnell et al. | Mar 2011 | A1 |
20110070318 | Jezek et al. | Mar 2011 | A1 |
20110071168 | Chopp et al. | Mar 2011 | A1 |
20110076313 | Av-Gay et al. | Mar 2011 | A1 |
20110104240 | Jones et al. | May 2011 | A1 |
20110106000 | Jones et al. | May 2011 | A1 |
Number | Date | Country |
---|---|---|
0 805 678 | Oct 2003 | EP |
0 746 327 | Apr 2004 | EP |
0 724 436 | Jul 2004 | EP |
1 411 908 | May 2005 | EP |
1 163 528 | Nov 2005 | EP |
1 681 068 | Jul 2006 | EP |
1 690 532 | Aug 2006 | EP |
1 690 554 | Aug 2006 | EP |
1 690 557 | Aug 2006 | EP |
1 690 558 | Aug 2006 | EP |
1 700 611 | Sep 2006 | EP |
1 704 876 | Sep 2006 | EP |
1 704 877 | Sep 2006 | EP |
1 704 879 | Sep 2006 | EP |
1 707 224 | Oct 2006 | EP |
1 728 438 | Dec 2006 | EP |
1 731 176 | Dec 2006 | EP |
1 757 278 | Feb 2007 | EP |
1 764 119 | Mar 2007 | EP |
1 790 335 | May 2007 | EP |
1 861 130 | Sep 2008 | EP |
1 343 547 | Apr 2009 | EP |
1 871 433 | Apr 2009 | EP |
1 161 248 | May 2009 | EP |
1 846 058 | Jul 2009 | EP |
2 233 437 | Sep 2010 | EP |
WO 9507691 | Mar 1995 | WO |
WO 9510267 | Apr 1995 | WO |
WO 9512394 | May 1995 | WO |
WO 9519767 | Jul 1995 | WO |
WO 9522335 | Aug 1995 | WO |
WO 9532715 | Dec 1995 | WO |
WO 9608966 | Mar 1996 | WO |
WO 9613164 | May 1996 | WO |
WO 9614844 | May 1996 | WO |
WO 96015781 | May 1996 | WO |
WO 9615797 | May 1996 | WO |
WO 9627386 | Sep 1996 | WO |
WO 9632118 | Oct 1996 | WO |
WO 9632136 | Oct 1996 | WO |
WO 96033757 | Oct 1996 | WO |
WO 9635416 | Nov 1996 | WO |
WO 9716983 | May 1997 | WO |
WO 9731654 | Sep 1997 | WO |
WO 9734014 | Sep 1997 | WO |
WO 97047254 | Dec 1997 | WO |
WO 9805689 | Feb 1998 | WO |
WO 9806389 | Feb 1998 | WO |
WO 9808482 | Mar 1998 | WO |
WO 9808482 | Mar 1998 | WO |
WO 9808496 | Mar 1998 | WO |
WO 9813358 | Apr 1998 | WO |
WO 9819996 | May 1998 | WO |
WO 9820015 | May 1998 | WO |
WO 9822090 | May 1998 | WO |
WO 9829101 | Jul 1998 | WO |
WO 9842661 | Oct 1998 | WO |
WO 9900070 | Jan 1999 | WO |
WO 9901427 | Jan 1999 | WO |
WO 9918949 | Apr 1999 | WO |
WO 9922729 | May 1999 | WO |
WO 9933823 | Jul 1999 | WO |
WO 9937616 | Jul 1999 | WO |
WO 9944595 | Sep 1999 | WO |
WO 9944595 | Sep 1999 | WO |
WO 9951221 | Oct 1999 | WO |
WO 9967210 | Dec 1999 | WO |
WO 9967296 | Dec 1999 | WO |
WO 0003640 | Jan 2000 | WO |
WO 0006151 | Feb 2000 | WO |
WO 0030658 | Jun 2000 | WO |
WO 0033877 | Jun 2000 | WO |
WO 0056333 | Sep 2000 | WO |
WO 0059304 | Oct 2000 | WO |
WO 0063462 | Oct 2000 | WO |
WO 0076318 | Dec 2000 | WO |
WO 0112067 | Feb 2001 | WO |
WO 0115738 | Mar 2001 | WO |
WO 0115738 | Mar 2001 | WO |
WO 0126702 | Apr 2001 | WO |
WO 0126702 | Apr 2001 | WO |
WO 0145732 | Jun 2001 | WO |
WO 0145732 | Jun 2001 | WO |
WO 0170199 | Sep 2001 | WO |
WO 0185227 | Nov 2001 | WO |
WO 0185227 | Nov 2001 | WO |
WO 0189572 | Nov 2001 | WO |
WO 0217880 | Mar 2002 | WO |
WO 0217880 | Mar 2002 | WO |
WO 02017881 | Mar 2002 | WO |
WO 02017881 | Mar 2002 | WO |
WO 0220026 | Mar 2002 | WO |
WO 0220026 | Mar 2002 | WO |
WO 0232418 | Apr 2002 | WO |
WO 0234705 | May 2002 | WO |
WO 0243786 | Jun 2002 | WO |
WO 0243786 | Jun 2002 | WO |
WO 0247675 | Jun 2002 | WO |
WO 02051353 | Jul 2002 | WO |
WO 02051353 | Jul 2002 | WO |
WO 02056864 | Jul 2002 | WO |
WO 02056864 | Jul 2002 | WO |
WO 02056874 | Jul 2002 | WO |
WO 02056904 | Jul 2002 | WO |
WO 02070496 | Sep 2002 | WO |
WO 02076395 | Oct 2002 | WO |
WO 02076395 | Oct 2002 | WO |
WO 03004097 | Jan 2003 | WO |
WO 03006427 | Jan 2003 | WO |
WO 03015605 | Feb 2003 | WO |
WO 03015605 | Feb 2003 | WO |
WO 03017989 | Mar 2003 | WO |
WO 03026717 | Apr 2003 | WO |
WO 03030659 | Apr 2003 | WO |
WO 03041713 | May 2003 | WO |
WO 03047636 | Jun 2003 | WO |
WO 03047636 | Jun 2003 | WO |
WO 03080039 | Oct 2003 | WO |
WO 03092763 | Nov 2003 | WO |
WO 03095398 | Nov 2003 | WO |
WO 03095398 | Nov 2003 | WO |
WO 2004009066 | Jan 2004 | WO |
WO 2004009253 | Jan 2004 | WO |
WO 2004011421 | Feb 2004 | WO |
WO 2004012874 | Feb 2004 | WO |
WO 2004037798 | May 2004 | WO |
WO 2004039313 | May 2004 | WO |
WO 2004039313 | May 2004 | WO |
WO 2004060283 | Jul 2004 | WO |
WO 2004064767 | Aug 2004 | WO |
WO 2004064767 | Aug 2004 | WO |
WO 2004087212 | Oct 2004 | WO |
WO 2004098538 | Nov 2004 | WO |
WO 2004098538 | Nov 2004 | WO |
WO 2005003032 | Jan 2005 | WO |
WO 2005011575 | Feb 2005 | WO |
WO 2005011575 | Feb 2005 | WO |
WO 2005030118 | Apr 2005 | WO |
WO 2005030118 | Apr 2005 | WO |
WO 2005030135 | Apr 2005 | WO |
WO 2005030135 | Apr 2005 | WO |
WO 2005030147 | Apr 2005 | WO |
WO 2005030147 | Apr 2005 | WO |
WO 2005034860 | Apr 2005 | WO |
WO 2005034860 | Apr 2005 | WO |
WO 2005039664 | May 2005 | WO |
WO 2005039664 | May 2005 | WO |
WO 2005067986 | Jul 2005 | WO |
WO 2005070006 | Aug 2005 | WO |
WO 2005070006 | Aug 2005 | WO |
WO 2005070008 | Aug 2005 | WO |
WO 2005070008 | Aug 2005 | WO |
WO 2005070874 | Aug 2005 | WO |
WO 2005070883 | Aug 2005 | WO |
WO 2005072819 | Aug 2005 | WO |
WO 2005077962 | Aug 2005 | WO |
WO 2005077962 | Aug 2005 | WO |
WO 2005081752 | Sep 2005 | WO |
WO 2005081752 | Sep 2005 | WO |
WO 2005081964 | Sep 2005 | WO |
WO 2005094913 | Oct 2005 | WO |
WO 2005102282 | Nov 2005 | WO |
WO 2005107384 | Nov 2005 | WO |
WO 2005107384 | Nov 2005 | WO |
WO 2005112954 | Dec 2005 | WO |
WO 2005115440 | Dec 2005 | WO |
WO 2005115440 | Dec 2005 | WO |
WO 2005120493 | Dec 2005 | WO |
WO 2006023693 | Mar 2006 | WO |
WO 2006023693 | Mar 2006 | WO |
WO 2006037105 | Apr 2006 | WO |
WO 2006037105 | Apr 2006 | WO |
WO 2006041855 | Apr 2006 | WO |
WO 2006041855 | Apr 2006 | WO |
WO 2006045639 | May 2006 | WO |
WO 2006055542 | May 2006 | WO |
WO 2006055542 | May 2006 | WO |
WO 2006058318 | Jun 2006 | WO |
WO 2006064056 | Jun 2006 | WO |
WO 2006066362 | Jun 2006 | WO |
WO 2006084909 | Aug 2006 | WO |
WO 2006084910 | Aug 2006 | WO |
WO 2006084911 | Aug 2006 | WO |
WO 2006084912 | Aug 2006 | WO |
WO 2006084913 | Aug 2006 | WO |
WO 2006084914 | Aug 2006 | WO |
WO 2006095193 | Sep 2006 | WO |
WO 2006095193 | Sep 2006 | WO |
WO 2006096572 | Sep 2006 | WO |
WO 2006097348 | Sep 2006 | WO |
WO 2006099058 | Sep 2006 | WO |
WO 2006099058 | Sep 2006 | WO |
WO 2006100154 | Sep 2006 | WO |
WO 2006100155 | Sep 2006 | WO |
WO 2006100156 | Sep 2006 | WO |
WO 2006122960 | Nov 2006 | WO |
WO 2006122961 | Nov 2006 | WO |
WO 2006125016 | Nov 2006 | WO |
WO 2006125262 | Nov 2006 | WO |
WO 2006127591 | Nov 2006 | WO |
WO 2006127591 | Nov 2006 | WO |
WO 2006128121 | Nov 2006 | WO |
WO 2006128742 | Dec 2006 | WO |
WO 2006128742 | Dec 2006 | WO |
WO 2006128743 | Dec 2006 | WO |
WO 2006130982 | Dec 2006 | WO |
WO 2007003028 | Jan 2007 | WO |
WO 2007005910 | Jan 2007 | WO |
WO 2007005910 | Jan 2007 | WO |
WO 2007012165 | Feb 2007 | WO |
WO 2007016677 | Feb 2007 | WO |
WO 2007016677 | Feb 2007 | WO |
WO 2007023005 | Mar 2007 | WO |
WO 2007024501 | Mar 2007 | WO |
WO 2007024501 | Mar 2007 | WO |
WO 2007027859 | Mar 2007 | WO |
WO 2007028657 | Mar 2007 | WO |
WO 2007030266 | Mar 2007 | WO |
WO 2007030266 | Mar 2007 | WO |
WO 2007050379 | May 2007 | WO |
WO 2007050379 | May 2007 | WO |
WO 2007053292 | May 2007 | WO |
WO 2007053578 | May 2007 | WO |
WO 2007053578 | May 2007 | WO |
WO 2007054373 | May 2007 | WO |
WO 2007057763 | May 2007 | WO |
WO 2007057763 | May 2007 | WO |
WO 2007059311 | May 2007 | WO |
WO 2007059311 | May 2007 | WO |
WO 2007064895 | Jun 2007 | WO |
WO 2007064895 | Jun 2007 | WO |
WO 2007067477 | Jun 2007 | WO |
WO 2007084533 | Jul 2007 | WO |
WO 2007084533 | Jul 2007 | WO |
WO 2007086884 | Aug 2007 | WO |
WO 2007086884 | Aug 2007 | WO |
WO 2007088050 | Aug 2007 | WO |
WO 2007088050 | Aug 2007 | WO |
WO 2007088123 | Aug 2007 | WO |
WO 2007088123 | Aug 2007 | WO |
WO 2007092284 | Aug 2007 | WO |
WO 2007092284 | Aug 2007 | WO |
WO 2007100910 | Sep 2007 | WO |
WO 2007100910 | Sep 2007 | WO |
WO 2007103190 | Sep 2007 | WO |
WO 2007103190 | Sep 2007 | WO |
WO 2007127725 | Nov 2007 | WO |
WO 2007127725 | Nov 2007 | WO |
WO 2007133922 | Nov 2007 | WO |
WO 2007133922 | Nov 2007 | WO |
WO 2007143185 | Dec 2007 | WO |
WO 2007143185 | Dec 2007 | WO |
WO 2007149437 | Dec 2007 | WO |
WO 2007149520 | Dec 2007 | WO |
WO 2007149520 | Dec 2007 | WO |
WO 2008005313 | Jan 2008 | WO |
WO 2008005313 | Jan 2008 | WO |
WO 2008013633 | Jan 2008 | WO |
WO 2008013633 | Jan 2008 | WO |
WO 2008020218 | Feb 2008 | WO |
WO 2008027203 | Mar 2008 | WO |
WO 2008027203 | Mar 2008 | WO |
WO 2008062160 | May 2008 | WO |
WO 2008071242 | Jun 2008 | WO |
WO 2008088507 | Jul 2008 | WO |
WO 2008088507 | Jul 2008 | WO |
WO 2008095841 | Aug 2008 | WO |
WO 2008095841 | Aug 2008 | WO |
WO 2008098192 | Aug 2008 | WO |
WO 2008098192 | Aug 2008 | WO |
WO 2008100591 | Aug 2008 | WO |
WO 2008100591 | Aug 2008 | WO |
WO 2008112391 | Sep 2008 | WO |
WO 2008112391 | Sep 2008 | WO |
WO 2008116497 | Oct 2008 | WO |
WO 2008116925 | Oct 2008 | WO |
WO 2008130567 | Oct 2008 | WO |
WO 2008141416 | Nov 2008 | WO |
WO 2008150505 | Dec 2008 | WO |
WO 2008157393 | Dec 2008 | WO |
WO 2009014616 | Jan 2009 | WO |
WO 2009014829 | Jan 2009 | WO |
WO 2009014829 | Jan 2009 | WO |
WO 2009019498 | Feb 2009 | WO |
WO 2009019498 | Feb 2009 | WO |
WO 2009019499 | Feb 2009 | WO |
WO 2009026680 | Mar 2009 | WO |
WO 2009036571 | Mar 2009 | WO |
WO 2009049208 | Apr 2009 | WO |
WO 2009064861 | May 2009 | WO |
WO 2009064861 | May 2009 | WO |
WO 2009073643 | Jun 2009 | WO |
WO 2009073643 | Jun 2009 | WO |
WO 2009073940 | Jun 2009 | WO |
WO 2009073940 | Jun 2009 | WO |
WO 2009080795 | Jul 2009 | WO |
WO 2009086470 | Jul 2009 | WO |
WO 2009086470 | Jul 2009 | WO |
WO 2009088433 | Jul 2009 | WO |
WO 2009098113 | Aug 2009 | WO |
WO 2009117182 | Sep 2009 | WO |
WO 2009117182 | Sep 2009 | WO |
WO 2009117183 | Sep 2009 | WO |
WO 2009124379 | Oct 2009 | WO |
WO 2009131931 | Oct 2009 | WO |
WO 2009155689 | Dec 2009 | WO |
WO 2009155690 | Dec 2009 | WO |
WO 2010002450 | Jan 2010 | WO |
WO 2010002450 | Jan 2010 | WO |
WO 2010033242 | Mar 2010 | WO |
WO 2010033242 | Mar 2010 | WO |
WO 2010045465 | Apr 2010 | WO |
WO 2010048724 | May 2010 | WO |
WO 2010080213 | Jul 2010 | WO |
WO 2010080213 | Jul 2010 | WO |
WO 2010096320 | Aug 2010 | WO |
WO 2010096320 | Aug 2010 | WO |
WO 2010114669 | Oct 2010 | WO |
WO 2010120414 | Oct 2010 | WO |
WO 2010151505 | Dec 2010 | WO |
WO 2012118819 | Sep 2012 | WO |
Entry |
---|
Frost et al., Synthesis, characterization, and controlled nitric oxide release from S-nitrosothiol-derivatized fumed silica polymer filler particles, Wiley Periodicals, J. Biomed. Mater. Res. 72A: 409-419, 2005. |
Al-Sa'Doni et al., “S-Nitrosothiols as Nitric Oxide-Donors: Chemistry, Biology and Possible Future Therapeutic Applications”, Current Medicinal Chemistry, 2004, 11: 2679-2690. |
Al-Sa'Doni et al., “Current Status and Future Possibilities of Nitric Oxide-Donor Drugs: Focus on S-Nitrosothiols”, Mini-Reviews in Medicinal Chemistry, 2005, 5: 247-254. |
Albert, Klaus, “NMR investigations of stationary phases”, Journal of Separation Science, 2003, 26: 215-224. |
Bainbrigge et al., “The thermal stability of S-nitrosothiols: experimental studies andab initio calculations on model compounds”, Journal of the Chemical Society, Perkin Transactions, 1997, 2: 351-353. |
Bartberger et al., “Theory, Spectroscopy, and Crystallographic Analysis of S-Nitrosothiols: Conformational Distribution Dictates Spectroscopic Behavior”, Journal of the American Chemical Society, 2000, 122: 5889-5890. |
Bogush et al., “Preparation of Monodisperse Silica Particles: Control of Size and Mass Fraction”, Journal of Non-Crystalline Solids, 1988, 104: 95-106. |
Branda et al., “The effect of mixing alkoxides on the Stober particles size”, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2007, 299: 252-255. |
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 3, “Hydrolysis and Condensation II: Silicates”, pp. 97-234, 1990. |
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 4, “Particulate Sols and Gels”, pp. 235-302, 1990. |
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 8, “Drying”, pp. 453-514, 1990. |
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 9, “Structural Evolution During Consolidation”, pp. 515-616, 1990. |
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 10, “Surface Chemistry and Chemical Modification”, pp. 617-674, 1990. |
Brinker et al., Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Chapter 13, “Film Formation”, pp. 787-838, 1990. |
Brunner et al., “In Vitro Cytotoxicity of Oxide Nanoparticles: Comparison to Asbestos, Silica, and the Effect of Particle Solubility”, Environmental Science and Technology, 2006, 40: 4374-4381. |
Butler et al., “Chemistry, Analysis, and Biological Roles of S-Nitrosothiols”, Analytical Biochemistry, 1997, 249: 1-9. |
Cassidy et al., “Drug delivery strategies for photodynamic antimicrobial chemotherapy: From benchtop to clinical practice”, Journal Photochemistry and Photobiology B: Biology, 2009, 95(2): 71-80, (Abstract Only). |
Charville et al., “Reduced bacterial adhesion to fibrinogen-coated substrates via nitric oxide release”, Biomaterials, 2008, 29(30): 4039-4044. |
Coneski et al., “Degradable Nitric Oxide-Releasing Biomaterials via Post-Polymerization Functionalization of Cross-Linked Polyesters”, Biomacromolecules, 2010, 11: 3208-3215. |
Coneski et al., “Synthesis of nitric oxide-releasing polyurethanes with S-nitrosothiol-containing hard and soft segments”, Polymer Chemistry, 2011, 2: 906-913. |
Cooke, John, “NO and angiogenesis”, Atherosclerosis Supplements, 2003, 4: 53-60. |
Crichton et al., “Old Iron, Young Copper: from Mars to Venus”, BioMetals, 2001, 14: 99-112. |
De Souza et al., “Leishmanicidal activity of primary S-nitrosothiols against Leishmania major and Leishmania amazonensis: Implications for the treatment of cutaneous leishmaniasis”, Nitric Oxide, 2006, 15: 209-216. |
Deupree et al., “Morphological analysis of the antimicrobial action of nitric oxide on Gram-negative pathogens using atomic force microscopy”, Acta Biomaterialia, 2009, 5:1405-1415. |
Dicks et al., “Identification of Cu+ as the effective reagent in nitric oxide formation from S-nitrosothiols (RSNO)”, Journal of the Chemical Society, 1996, 2: 481-487. |
Dobmeier et al., “Nitric Oxide-Releasing Xerogel-Based Fiber-Optic pH Sensors”, Analytical Chemistry, 2006, 78: 7461-7466. |
Etchenique et al., “Photodelivery of Nitric Oxide from a Nitrosothiol-Derivatized Surface”, Journal of the American Chemical Society, 2000, 122: 3967-3968. |
Foster et al., “Photocatalytic disinfection using titanium dioxide: spectrum and mechanism of antimicrobial activity”, Applied Microbiology Biotechnology, 2011, 90(6): 1847-1868. |
Frost et al., “Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices”, Biomaterials, 2005, 26(14): 1685-1695. |
Garcia et al., “S-Nitroso-N-Acetylcysteine (SNAC) Prevents Myocardial Alterations in Hypercholesterolemic LDL Receptor Knockout Mice by Antiinflammatory Action”, Journal of Cardiovascular Pharmacology and Therapeutics, 2008, 51: 78-85. |
Gaslain et al., “One-step preparation of thiol-modified mesoporous silica spheres with various functionalization levels and different pore structures”, Journal of Sol-Gel Science and Technology, 2009, 49: 112-124. |
Grossi et al., “A Kinetic Study of S-Nitrosothiol Decomposition”, Chemistry—A European Journal, 2002, 8(2): 380-387. |
Hatton et al., “Past, Present, and Future of Periodic Mesoporous Organosilicas—The PMOs”, Accounts of Chemical Research, 2005, 38: 305-312. |
Hetrick et al., “Reducing implant-related infections: active release strategies”, Chemical Society Reviews, 2006, 35: 780-789. |
Hetrick et al., “Reduced foreign body response at nitric oxide-releasing subcutaneous implants”, Biomaterials, 2007, 28(31): 4571-4580. |
Hetrick et al., “Antibacterial nitric oxide-releasing xerogels: Cell viability and parallel plate flow cell adhesion studies”, Biomaterials, 2007, 28(11): 1948-1956. |
Hogg, Neil, “Biological Chemistry and Clinical Potential of S-Nitrosothiols”, Free Radical Biology & Medicine, 2000, 28(10): 1478-1486. |
Huang et al., “Synthesis of uniform, spherical sub-100 nm silica particles using a conceptual modification of the classic LaMer model”, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2010, 360: 175-183. |
International Preliminary Report on Patentability corresponding to International Application No. PCT/US2012/026960; mailed Mar. 13, 2014; 6 pages. |
International Preliminary Report on Patentability corresponding to International Application No. PCT/US2012/026972; mailed Mar. 13, 2014; 6 pages. |
Johnston et al., “Porous functionalised silica particles: a potential platform for biomolecular screening”, Chemical Communications, 2005, p. 848-850. |
Johnston et al., “A Mechanism for Forming Large Fluorescent Organo-Silica Particles: Potential Supports for Combinatorial Synthesis”, Chemistry of Materials, 2006, 18: 6163-6169. |
Katayama et al., “Design and Evaluation of S-Nitrosylated Human Serum Albumin as a Novel Anticancer Drug”, The Journal of Pharmacology and Experimental Therapeutics, 2008, 325(1): 69-76. |
Katsumi et al., “Physicochemical, Tissue Distribution, and Vasodilation Characteristics of Nitrosated Serum Albumin: Delivery of Nitric Oxide In Vivo”, Journal of Pharmaceutical Sciences, 2004, 93(9): 2343-2352. |
Katsumi et al., “Development of Polyethylene Glycol-Conjugated Poly-S-Nitrosated Serum Albumin, a Novel S-Nitrosothiol for Prolonged Delivery of Nitric Oxide in the Blood Circulation in Vivo”, The Journal of Pharmacology and Experimental Therapeutics, 2005, 314(3): 1117-1124. |
Kim et al., “Effect of electrolyte additives on sol-precipitated nano silica particles”, Ceramics International, 2004, 30: 171-175. |
Kim et al., “Size Control of Silica Nanoparticles and Their Surface Treatment for Fabrication of Dental Nanocomposites”, Biomacromolecules, 2007, 8: 215-222. |
Langford et al., “Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty”, The Lancet, 1994, 344: 1458-1460. |
Laszlo et al., “Attenuation by nitrosothiol NO donors of acute intestinal microvascular dysfunction in the rat”, British Journal of Pharmacology, 1995, 115: 498-502. |
Lee et al., “Preparation of Highly Monodispersed Hybrid Silica Spheres Using a One-Step Sol-Gel Reaction in Aqueous Solution”, Langmuir, 2007, 23(22): 10875-10878. |
Lin et al., “Structural and Morphological Control of Cationic Surfectant-Templated Mesoporous Silica”, Accounts of Chemical Research, 2002, 35: 927-935. |
Lin et al., “Preparation of functionalized tertiary thiols and nitrosothiols”, Tetrahedron, 2006, 62(35): 8410-8418. |
Marxer et al., “Preparation of Nitric Oxide (NO)-Releasing Sol-Gels for Biomaterial Application”, Chemistry of Materials, 2003, 15: 4193-4199. |
Marxer et al., “Sol-gel derived nitric oxide-releasing oxygen sensors”, Analyst, 2005, 130: 206-212. |
Meng et al., “Preparation of Highly Monodisperse Hybrid Silica Nanospheres Using a One-Step Emulsion Reaction in Aqueous Solution”, Langmuir, 2009, 25(14): 7879-7883. |
Miller et al., “Functionalized Organosilica Microspheres via a Novel Emulsion-Based Route”, Langmuir, 2005, 21: 9733-9740. |
Mocellin et al., “Nitric Oxide, a Double Edged Sword in Cancer Biology: Searching for Therapeutic Opportunities”, Medicinal Research Reviews, 2007, 27: 317-352. |
Mosquera et al., “New route for producing crack-free xerogels: Obtaining uniform pore size”, Journal of Non-Crystalline Solids, 2008, 354: 645-650. |
Mowery et al., “Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release”, Biomaterials, 2000, 21: 9-21. |
Nablo et al., “Sol-Gel Derived Nitric-Oxide Releasing Materials that Reduce Bacterial Adhesion”, Journal of the American Chemical Society, 2001, 123: 9712-9713. |
Nablo et al., “Antibacterial properties of nitric oxide-releasing sol-gels”, Journal of Biomedical Materials Research Part A, 2003, 67A: 1276-1283. |
Nablo et al., “Poly(vinyl chloride)-Coated Sol-Gels for Studying the Effects of Nitric Oxide Release on Bacterial Adhesion”, Biomacromolecules, 2004, 5: 2034-2041. |
Nablo et al., “Inhibition of implant-associated infections via nitric oxide release”, Biomaterials, 2005, 26(34): 6984-6990. |
Nablo et al., “Nitric oxide-releasing sol-gels as antibacterial coatings for orthopedic implants”, Biomaterials, 2005, 26: 917-924. |
Nakamura et al., “Synthesis and Characterization of Organosilica Nanoparticles Prepared from 3-Mercaptopropyltrimethoxysilane as the Single Silica Source”, The Journal of Physical Chemistry C, 2007, 111: 18892-18898. |
Nakamura et al., “One-Pot Synthesis and Characterization of Three Kinds of Thiol-Organosilica Nanoparticles”, Langmuir, 2008, 24: 5099-5108. |
Noimark et al., “The role of surfaces in catheter-associated infections”, Chemical Society Reviews, 2009, 38: 3435-3448. |
O'Halloran et al., “Metallochaperones, an Intracellular Shuttle Service for Metal Ions”, The Journal of Biological Chemistry, 2000, 275(33): 25057-25060. |
Osterholtz et al., “Kinetics of the hydrolysis and condensation of organofunctional alkoxysilanes: a review”, Journal of Adhesion Science and Technology, 1992, 6(1): 127-149. |
Page et al., “Antimicrobial surfaces and their potential in reducing the role of the inanimate environment in the incidence of hospital-acquired infections”, Journal Materials Chemistry—The Royal Society of Chemistry, 2009, 19: 3819-3831. |
Park et al., “Preparation of silica nanoparticles: determination of the optimal synthesis conditions for small and uniform particles”, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2002, 197: 7-17. |
Pavlos et al., “Photosensitive precursors to nitric oxide”, Current Topics in Medicinal Chemistry, 2005, 5: 635-645. |
Polizzi et al., “Water-Soluble Nitric Oxide-Releasing Gold Nanoparticles”, Langmuir, 2007, 23: 4938-4943. |
Privett et al., “Efficacy of surface-generated nitric oxide against Candida albicans adhesion and biofilm formation”, Biofouling, 2010, 26(8): 973-983. |
Radomski et al., “S-nitroso-glutathione inhibits platelet activation in vitro and in vivo”, British Journal of Pharmacology, 1992, 107: 745-749. |
Rahman et al., “An optimized sol-gel synthesis of stable primary equivalent silica particles”, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2007, 294: 102-110. |
Ramsay et al., “Systemic effects of S-nitroso-glutathione in the human following intravenous infusion”, British Journal of Clinical Pharmacology, 1995, 40: 101-102. |
Rao et al., “Synthesis of flexible silica aerogels using methyltrimethoxysilane (MTMS) precursor”, Journal Colloid Interface Science, 2006, 300: 279-285. |
Reynolds et al., “Nitric Oxide-Releasing Hydrophobic Polymers: Preparation, Characterization, and Potential Biomedical Applications”, Free Radical Biology & Medicine, 2004, 37(7): 926-936. |
Riccio et al., “Stöber Synthesis of Nitric Oxide-Releasing S-Nitrosothiol-Modified Silica Particles”, Chemistry of Materials, 2011, 23: 1727-1735. |
Richardson et al., “Potential therapeutic uses for S-nitrosothiols”, Clinical Science, 2002, 102: 99-105. |
Rojas et al., “Polyurethane coating release bioactive antibodies to reduce bacterial adhesion”, Journal of Controlled Release, 2000, 63: 175-189. |
Sakka et al., “Formation of sheets and coating films from alkoxide solutions”, Journal Non-Crystalline Solids, 1984, 63(1-2): 223-235. |
Scherer, George, “Effect of Shrinkage on the Modulus of Silica Gel”, Journal of Non-Crystalline Solids, 1989, 109: 183-190. |
Schmidt, H., “Organically Modified Silicates by the Sol-Gel Process”, Materials Research Society Symposia Proceedings, 1984, 32: 327-335. |
Schmidt et al., “Principles of hydrolysis and condensation of alkoxysilanes”, Journal Non-Crystalline Solids, 1984, 63(1-2): 1-11. |
Seabra et al., “Polynitrosated Polyesters: Preparation, Characterization, and Potential Use for Topical Nitric Oxide Release”, Biomacromolecules, 2005, 6: 2512-2520. |
Seabra et al., “Nitric oxide-releasing vehicles for biomedical applications”, Journal of Materials Chemistry, 2009, 20: 1624-1637. |
Seabra et al., “Antibacterial Nitric Oxide-Releasing Polyester for the Coating of Blood-Contacting Artificial Materials”, Artificial Organs, 2010, 34(7): E204-E214. |
Shin et al., “Inorganic/Organic Hybrid Silica Nanoparticles as a Nitric Oxide Delivery Scaffold”, Chemistry of Materials, 2008, 20: 239-249. |
Sinha et al., “UV-induced DNA damage and repair: a review”, Photochemical & Photobiological Sciences, 2002, 1: 225-236. |
Sortino et al., “Light-controlled nitric oxide delivering molecular assemblies”, Chemical Society Reviews, 2010, 39: 2903-2913. |
Stasko et al., “S-Nitrosothiol-Modified Dendrimers as Nitric Oxide Delivery Vehicles”, Biomacromolecules, 2008, 9(3):834-841. |
Stein et al., “Hybrid Inorganic-Organic Mesoporous Silicates—Nanoscopic Reactors Coming of Age”, Advanced Materials, 2000, 12(19): 1403-1419. |
Stober et al., “Controlled Growth of Monodisperse Silica Spheres in the Micron Size Range”, Journal of Colloid and Interface Science, 1968, 26: 62-69. |
Tan et al., “Study of the Effects of Progressive Changes in Alkoxysilane Structure on Sol-Gel Reactivity”, The Journal of Physical Chemistry B, 2006, 110: 22353-22364. |
Valko et al., “Metals, Toxicity and Oxidative Stress”, Current Medicinal Chemistry, 2005, 12: 1161-1208. |
Van Helden et al., “Preparation and Characterization of Spherical Monodisperse Silica Dispersions in Nonaqueous Solvents”, Journal of Colloid and Interface Science, 1981, 81(2): 354-368. |
Varu et al., “Basic Science Review: Nitric Oxide—Releasing Prosthetic Materials”, Vascular & Endovasc Surgery, 2009, 43: 121-131. |
Vogel et al., “Fluorescent organosilica micro- and nanoparticles with controllable size”, Journal of Colloid and Interface Science, 2007, 310: 144-150. |
Walcarius et al., “Rate of Access to the Binding Sites in Organically Modified Silicates. 3. Effect of Structure and Density of Functional Groups in Mesoporous Solids Obtained by the Co-Condensation Route”, Chemistry of Materials, 2003, 15: 4181-4192. |
Walshe et al., “Wilson's disease: the importance of measuring serum caeruloplasmin non-immunologically”, Annals of Clinical Biochemistry, 2003, 40: 115-121. |
Wang et al., “Nitric Oxide Donors: Chemical Activites and Biological Applications”, Chemical Reviews, 2002, 102: 1091-1134. |
Williams et al., “The Chemistry of S-Nitrosothials”, Accounts of Chemical Research, 1999, 32: 869-876. |
Williams et al., “A chemist's view of the nitric oxide story”, Organic & Biomolecular Chemistry, 2003, 1: 441-449. |
Yoo et al., “Influence of Reaction Parameters on Size and Shape of Silica Nanoparticles”, Journal of Nanoscience and Nanotechnology, 2006, 6: 3343-3346. |
Extended European Search Report corresponding to European Patent Application No. 12752627.5: 5 pages (mailed Jul. 2, 2015). |
Barbe et al., “Silica Particles: A Novel Drug-Delivery System”, Advanced Materials, 2004, 16(21): 1959-1965. |
Dobmeier et al., “Antibacterial Properties of Nitric Oxide-Releasing Sol-Gel Microarrays”, Biomacromolecules, 2004, 5: 2493-2495. |
Farias-Eisner et al., “The Chemistry and Tumoricidal Activity of Nitric Oxide/Hydrogen Peroxide and the Implications to Cell Resistance/Susceptibility”, The Journal of Biological Chemistry, 1996, 271(11): 6144-6151. |
Pulfer et al., “Incorporation of nitric oxide-releasing crosslinked polyethyleneimine microspheres into vascular grafts”, Journal of Biomedical Materials Research, 1997, 37(2): 182-189. |
Shin et al., “Nitric Oxide-Releasing Sol-Gel Particle/Polyurethane Glucose Biosensors”, Analytical Chemistry, 2004, 76: 4543-4549. |
English Translation of Chinese Office Action Corresponding to Chinese Patent Application No. 201080056580.6; Date of Issue: Feb. 25, 2015 (14 pages). |
Huang “The mechanism and technique of Sol-Gel” Chemical Industry Press 1st Edition: 15 pages (2005). |
Amadeu et al., “Nitric Oxide Donor Improves Healing if Applied on Inflammatory and Proliferative Disease” Journal of Surgical Research 149: 84-93 (2008). |
Ashutosh, K. et al., “Use of nitric oxide inhalationin chronic obstructive pulmonary disease” Thorax 55:109-113 (2000). |
Azizzadeh, B. et al., “Nitric Oxide Improve Cisplatin Cytotoxicity in Head and Neck Squamous Cell Carcinoma” Laryngoscope 111:1896-1900 (2001). |
Barst, R.J. et al., “Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension” Pulmonary Circulation 2(2):139-147 (2012). |
Barraud, N., et al., “Involvement of Nitric Oxide in Biofilm Dispersal of Pseudomonas aeruginosa” Journal of Bacteriology 188(21):7344-7353 (2006). |
Benz S. et al., “Effect of Nitric Oxide in Ischemia/Reperfusion of the Pancreas” Journal of Surgical Research 106(1):46-53, (2002). |
Bian K. et al., “Vascular System: Role of Nitric Oxide in Cardiovascular Diseases” The Journal of Clinical Hypertension 10(4):304-310 (2008). |
Bloch K.D. et al. “Inhaled NO as a therapeutic agent” Cardiovascular Research 75:339-348 (2007). |
Bohl Masters et al., “Effects of nitric oxide releasing vinyl poly(vinyl alcohol) hydrogel dressings on dermal wound healing in diabetic mice” Wound Repair and Regeneration 10(5): 286-294 (2002). |
Bonavida B. et al., “Novel therapeutic applications of nitric oxide donors in cancer: Roles in chemo- and immunosensitization to apoptosis and inhibition of metastases” Nitric Oxide (19) 2:152-157 (2008). |
Bonavida B. et al., “Therapeutic potential of nitric oxide in cancer” rug Resistance Updates 9(3):157-73 (2006). |
Boykin J.V. et al., “HBO mediates increased nitric oxide production associated with wound healing”, Wound Repair and Regeneration 12(2) (2004). |
Boykin Jr. J.V., “Wound Nitric Oxide Bioactivity: A Promising Diagnostic Indicator for Diabetic Foot Ulcer Management”, Journal of Wound, Ostomy & Continence Nursing 37(1):25-32 (2010). |
Bruch-Gerharz D. et al., “Nitric Oxide in Human Skin: Current Status and Future Prospects”, Journal of Investigative Dermatology 110:1-7 (1998). |
Cals-Grierson M.M. et al., “Nitric oxide function in the skin”, Nitric Oxide 10(4):179-193 (2004). |
Carlsson S. et al., “Intravesical Nitric Oxide Delivery for Prevention of Catheter-Associated Urinary Tract Infections” Antimicrobial Agents and Chemotherapy 49(6):2352 (2005). |
Coban, A., et al., “The Effect of Nitric Oxide Combined with Fluoroquinolones against Salmonellaenterica Serovar Typhimurium in Vitro,” Mem Inst Oswaldo Cruz, Rio de Janeiro, 98(3):419-423 (2003). |
De Groote M.A. et al., “NO Inhibitions: Antimicrobial Properties of Nitric Oxide”, Clinical Infectious Diseases 21 (Supplement 2):S162-S165 (1995). |
Fang F., “Mechanisms of Nitric Oxide-related Antimicrobial Activity” Journal of Clinical Investigation 99(12):2818-2825 (1997). |
Frederiksen L.J. et al., “Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling” Clinical Cancer Research 13:2199-2206 (2007). |
Frost et al., “Controlled Photoinitiated Release of Nitric Oxide from Polymer Films Containing S-Nitroso-N-acetyle-DL-penicillamine Derivatized Fumed Silixa Filler” Journal of the American Chemical Society 2004, 126(5):1348-1349. |
Frost et al., “Synthesis, characterization, and controlled nitric oxide release from S-nitrosothiol-derivatized fumed silica polymer filler particles” Journal of Biomedical Research, Part A, 72A:409-419 (2005). |
Ghaffari A. et al., “Potential application of gaseous nitric oxide as a topical antimicrobial agent” Nitric Oxide 14(1):21-29 (2006). |
Gupta, R., et al., “Bioactive materials for biomedical applications using sol-gel technology,” Biomedical Materials 3:1-15 (2008). |
Herman A.G. et al., “Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis” European Heart Journal 26:1945-1955 (2005). |
Hetrick E.M. et al., “Bactericidal Efficacy of Nitric Oxide-Releasing Silica Nanoparticles” ACS Nano 2(2):235-246 (2008). |
Hetrick et al., “Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles”, Biomaterials 30:2782-2789 (2009). |
Hirst D. et al., “Targeting nitric oxide for cancer therapy”, Journal of Pharmacy and Pharmacology 59:3-13 (2007). |
Howlin R. et al., “Nitric oxide-mediated dispersal and enhanced antibiotic sensitivity in pseudomonas aeruginosa biofilms from the cystic fibrosis lung”, Archives of Disease in Childhood 96:A45 (2011). |
Hrabie et al., “Chemistry of the nitric oxide-releasing diazeniumdiolate (“nitrosohydroxylamine”) functional group and its oxygen-substituted derivatives,” Chemical Reviews 102:1135-1154 (2002). |
Huerta S. et al., “Nitric oxide donors: Novel cancer therapeutics (Review)”, International Journal of Oncology 33:909-927 (2008). |
International Search Report and Written Opinion Corresponding to International Application No. PCT/US2012/26972; Date of Mailing: Feb. 28, 2012; 11 Pages. |
International Search Report and Written Opinion Corresponding to International Application No. PCT/US2012/26960; Date of Mailing: Feb. 28, 2012; 18 Pages. |
Iwakir, N. et al., Synthesis of Amphiphillic polysiloxanes and their properties for formation of nano-aggregates, Colloid and Polymer Science 287:577-582 (2009). |
Johnson T. A. et al., “Reduced ischemia/reperfusion injury via glutathione-initiated nitric oxide-releasing dendrimers”, Nitric Oxide, 2009, 7 Pages. |
Jones M.L. et al., “Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices”, Applied Microbiology and Biotechnology 88:401-407 (2010). |
Kiziltepe T. et al., “JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells”, Blood 110:709-718 (2007). |
Lamas S. et al., “Nitric oxide signaling comes of age: 20 years and thriving”, Cardiovascular Research 75:207-209 (2007). |
Liu X. et al., “Nitric Oxide Inhalation Improves Microvascular Flow and Decreases Infarction Size After Myocardial Ischemia and Reperfusion”, Journal of the American College of Cardiology, vol. 50, No. 8 (2007). |
Luo J. et al., “Nitric oxide: a newly discovered function on wound healing”, Acta Pharmacologica Sinica 26(3):259-264 (2005). |
McElhaney-Feser, G., et al., “Synergy of Nitric Oxide and Azoles against Candida Species In Vitro,” Antimicrobial Agents And Chemotherapy 42(9):2342-2346 (1998). |
McGrowder D. et al., “Therapeutic Uses of Nitric Oxide-donating Drugs in the Treatment of Cardiovascular Diseases” International Journal of Pharmacology 2(4): 366-373 (2006). |
Napoli C. et al., “Nitric oxide and atherosclerosis: An update”, Nitric Oxide 15(4):265-279 (2006). |
Phillips L. et al., “Nitric Oxide Mechanism of Protection in Ischemia and Reperfusion Injury”, Journal of Investigative Surgery 22:46-55 (2009). |
Riccio et al., “Nitric oxide-releasing S-nitrosothiol-modified xerogels” Biomaterials 30:4494-4502 (2009). |
Robson, MC, “Wound Infection. A Failure of Wound Healing Caused by an Imbalance of Bacteria,” Surgical Clinics of North America 77(3): 637-50 (1997). |
Rothrock A.R. et al., “Synthesis of Nitric Oxide-Releasing Gold Nanoparticles”, Journal of American Chemical Society 127:9362-9363 (2005). |
Saaral, NY, “The Equilibrium Between Endothelin-1/Nitric Oxide in Acne Vulgaris,” Istanbul Tip Fakultesi Dergisi Cilt, 2008, 71(4). |
Saavedra J.E. et al., “Esterase-Sensitive Nitric Oxide Donors of the Diazeniumdiolate Family: In Vitro Antileukemic Activity ”Journal of Medicinal Chemistry 43:261-269 (2000). |
Sato et al. “Dynamic Aspect of Reactive Oxygen and Nitric Oxide in Oral Cavity”, J. Clin. Biochem. Nutr. 42:8-13 (2008). |
Schäffer M.R. et al., “Diabetes-impaired healing and reduced wound nitric oxide synthesis: A possible pathophysiologic correlation”, Surgery 121(5):513-519 (1997). |
Schairer D.O. et al., “The potential of nitric oxide releasing therapies as antimicrobial agents” Virulence 3(3):271-279 (2012). |
Schulz R. et al., “Nitric oxide in myocardial ischemia/reperfusion injury”, Cardiovascular Research 61:402-413 (2004). |
Schwentker A. et al., “Nitric oxide and wound repair: role of cytokines?” Nitric Oxide 7(1):1-10 (2002). |
Shin et al. “Synthesis of Nitric Oxide-Releasing Silica Nanoparticles” Journal of American Chemical Society 129(15):4612-4619 (2007). |
Shin et al. “Supporting Information: Synthesis of Nitric Oxide-Releasing Silica Nanoparticles” Journal of American Chemical Society 129(15):S1-S4 (2007). |
Simeone A.M. et al., “N-(4-Hydroxyphenyl) retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells” Carcinogenesis 27(3):568-577 (2006). |
Siriussawakul A. et al. “Role of nitric oxide in hepatic ischemia-reperfusion injury”, World Journal of Gastroenterology 16(48): 6079-6086 (2010). |
Shi, HP et al., “The role of iNOS in wound healing” Surgery, vol. 130(2):225-229 (2001). |
Slowing et al. “Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers” Advanced Drug Delivery Reviews 60:1278-1288 (2008). |
Stasko, N., et al., “Dendrimers as a Scaffold for Nitric Oxide Release,” J. Am. Chem. Soc., 2006, vol. 128, pp. 8265-8271. |
Stevens E.V. et al., “Nitric Oxide-Releasing Silica Nanoparticle Inhibition of Ovarian Cancer Cell Growth”, Molecular Pharmaceutics 7(3):775-785 (2010). |
Summersgill, J., et al., “Killing of Legionella pneumophila by nitric oxide in γ-interferon-activated macrophages,” Journal of Leukocyte Biology 52:625-629 (1992). |
Tang, X., et al., “Synthesis of Beta-Lactamase Activated Nitric Oxide Donors,” Biorgania & Medicinal Chemistry Letters 13:1687-1690 (2003). |
Terpolilli N.A. et al., “Inhalation of Nitric Oxide Prevents Ischemic Brain Damage in Experimental Stroke by Selective Dilatation of Collateral Arterioles” Circulation Research 110:727-738 (2012). |
Thomas D.D. et al., “Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide”, Proceedings of the National Academy of Sciences 101(24):8894-8899 (2004). |
Weller R. “Nitric oxide donors and the skin: useful therapeutic agents?” Clinical Science 105:533-535 (2003). |
Wink D.A. et al., “The multifaceted roles of nitric oxide in cancer”, Carcinogenesis 19(5):711-721 (1998). |
Witte M.B. et al., “Nitric oxide enhances experimental wound healing in diabetes”, British Journal of Surgery 89:1594-1601 (2002). |
Witte M.B. et al., “Role of nitric oxide in wound repair”, The American Journal of Surgery 183(4):406-412 (2002). |
Yetik-Anacak G. et al., “Nitric oxide and the endothelium: History and impact on cardiovascular disease”, Vascular Pharmacology 45(5):268-276 (2006). |
Zhang H. et al., “Nitric Oxide-Releasing Fumed Silica Particles: Synthesis, Characterization, and Biomedical Application”, Journal of the American Chemical Society 125:5015-5024 (2003). |
Zhu, D., et al., “Corrosion protection of metals by water-based silane mixtures of bis-[trimethosysilylpropyl]amine and vinyltriacetoxysilane,” Progress in Organic Coatings 49:42-53 (2004). |
Zhu H. et al., “Effects of Nitric Oxide on Skin Burn Wound Healing”, Journal of Burn Care & Research 29(5):804-814 (2008). |
Zhu H. et al., “Nitric Oxide Accelerates the Recovery from Burn Wounds”, World Journal of Surgery 31: 624-631 (2007). |
European Search Report Corresponding to European Patent Application No. 09820905.9; Dated: Feb. 14, 2013; 7 Pages. |
Living Water Acid-Alkaline Balance http://www.livingwaterhealthsolutions.com/Articles/alkalize.php Accessed online Nov. 3, 2011. |
Salivary pH Testing https://allicincenter.com/pdf/ph—testing.pdf Accessed online Nov. 3, 2011. |
Number | Date | Country | |
---|---|---|---|
20130344334 A1 | Dec 2013 | US |
Number | Date | Country | |
---|---|---|---|
61447368 | Feb 2011 | US | |
61565694 | Dec 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2012/026960 | Feb 2012 | US |
Child | 13975930 | US |